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ABSTRACT
Determining the Roles of the Oligomerization and C-terminal Domains in Mutant p53
Gain-of-Function Activities

By
George K. Annor
Advisor: Professor Jill Bargonetti

The tumor suppressor p53 (TP53) gene is often mutated in cancer, with missense
mutations found in the central DNA binding domain, and less often in the oligomerization
domain (OD) and C-terminal domain (CTD). The OD and CTD have been found to be
critical for the tumor suppressor functionality of wild-type p53 (wtp53). Specific missense
mutations in the DNA binding domain have been found to confer new gain-of-function
(GOF) activities. Mutations that destabilize tetramer formation, or deletion of key lysine
residues within the CTD, downregulate the ability of wtp53 to transactivate (increase the
rate of transcription of) its target genes. We previously found that mutant p53 (mtp53)
R273H, which has lost tumor suppression function and has GOF, associates with
replicating DNA and promotes the chromatin association of replication-associated
proteins mini-chromosome maintenance 2 (MCM2), and poly ADP-ribose polymerase 1
(PARP1). Herein, we created dual mutants to test if the oligomerization state and/or
deletion of the CTD of mtp53 R273H played a role in chromatin binding oncogenic gainof-function (GOF) activities. We used site-directed mutagenesis to introduce point
mutations in the OD of wtp53 (R337C, A347D, L344P), and mtp53 R273H (R273H-
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R337C, R273H-A347D, R273H-L344P), expressing plasmids. We also used the
CRISPR/Cas9 gene editing system to generate two endogenous mutants in MDA-MB468 cells which encode mtp53 R273H. One with deletion within the mtp53 CTD
(R273HΔ381-388) and the other an OD-CTD deletion mutant (R273HΔ347-393). The
glutaraldehyde crosslinking assay revealed that both exogenously expressed wtp53 and
mtp53 R273H formed predominantly tetramers, while the single OD mutant A347D, and
the dual mtp53 R273H-A347D, formed predominantly dimers. The R337C, L344P, mtp53
R273H-R337C, and mtp53 R273H-L344P proteins formed predominantly monomers. The
exogenously expressed mtp53 R273H and the dual OD mutants, R273H-A347D, R273HR337C, and R273H-L344P were able to interact with chromatin. They were also found to
be in close nuclear proximity to PARP1 and MCM2 via the proximity ligation assay (PLA).
The MDA-MB-468 endogenously expressed mtp53 R273HΔ381-388 and R273HΔ347393 exhibited decreased chromatin interaction, and less interaction with PARP1 and
MCM2 as compared to the full-length R273H. In vivo mouse xenograft model experiments
with MDA-MB-468 cells orthotopically implanted into NOD scid gamma (NSG) mice
demonstrated that R273HΔ347-393 mtp53, and a mtp53 knockdown cell line
R273Hfs387, formed smaller tumors and less circulating tumor cells compared to the
parental cells. This suggested that the absence of the CTD, or depletion of mtp53 R273H,
decreases GOF R273H mediated tumor formation with a significant decrease in the levels
of circulating tumor cells assessed via flow cytometry. Our findings suggest that while
mtp53 R273H can form tetramers, tetramer formation is not required for the GOF
associated chromatin interactions, rather residues within the CTD are critical for the
observed GOF mtp53 oncogenic abilities.
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CHAPTER 1
INTRODUCTION
1.1 History of p53 protein
The tumor suppressor protein 53 (TP53) is a 53kDa protein that was first identified
in 1979 by Arnold Levine and David Lane while working with the simian virus 40 (SV40)
large T-antigen1,2. During the first decade of its discovery, the p53 protein was widely
regarded as a proto-oncogene1,3. Researchers observed that newly cloned p53 cDNA
cooperated efficiently with oncogenic Ras when ectopically expressed in primary cells in
culture, which resulted in the transformation of the primary cells as well as immortalization
of such cells when p53 cDNA was overexpressed alone4. Furthermore, overexpression
of p53 in p53-null cells resulted in an increase in the tumorigenicity of the cells4-6.
When researchers compared the sequences of different cloned p53 cDNA, there
were significant differences between the clones suggesting that the p53 proteins were not
wild-type4–6. The proto-oncogenic role attributed to p53 was due to working with mutated
forms of the p53 protein7. The wild-type role of p53 wasn’t apparent until findings in 1989
counteracted its widely accepted proto-oncogenic roles5,8. Vogelstein and others
discovered that key signatures in colorectal cancers were deletions, insertions, and
missense mutations in the TP53 gene5,7,8. In that same year, the ability of oncogenes to
transform cells was shown to be suppressed by wild-type p53 cloned from nontransformed cells 4,9
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1.2 Structure and Function of wild-type p53
The p53 protein is a 393 polypeptide protein encoded by the TP53 gene which lies
on chromosome 17.p13.1 in the human genome7. It is composed of 11 exons and has 5
main domains. The domain architecture of p53 protein from the N-terminus to the Cterminus are (i) Transactivation domain (TA) residues 1-61 (ii) Proline-Rich region (PR)
residues 64-94 (iii) Site specific DNA binding domain (DBD) residues 100-300 (iv)
Oligomerization domain (OD) residues 323-355 and (v) a regulatory C-terminal domain
(CTD) residues 364-393 (Figure 1.2A)9,10.
TP53 codes for the p53 protein, a transcription factor that is often regarded as the
guardian of the genome due to its role in ensuring genomic stability7. In unstressed cells,
p53 has a relatively short half-life and is kept at low concentration by its interaction with
an E3 ubiquitin ligase mouse double minute-2 (MDM2) which targets p53 for proteasomal
degradation11,12. MDM2 is also a transcriptional target of p53, which serves to keep both
MDM2 and p53 proteins maintained at basal levels via a negative feedback loop. The
regulation of p53 is also aided by an MDM2-related protein MDM4/X, which lacks the
ability to ubiquitinate p53 but can inhibit p53 by directly interacting with p53 and also by
binding MDM2 to enhance its ability to ubiquitinate p5313,14 (Figure 1.2B).
In response to cellular stress such as hypoxia, oxidative stress, nutrient
deprivation, DNA damage, and ribonucleotide depletion, p53 is stabilized by the
phosphorylation of amino acid residues Ser15 and Ser20 by ATM (ataxia telangiectasia
mutated) and ATR (ataxia telangiectasia and Rad3-related protein) kinases.

This

phosphorylation impedes the interaction between p53, MDM2 and MDMX15,16.
Additionally, phosphorylation of MDM2 and MDMX prevents MDM2-dependent
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proteasomal degradation of p5316. As p53 levels rise, monomeric p53 associates into
dimers in the cytoplasm and is transported into the nucleus12. The oligomerization domain
(OD) directs a dimer-of-dimers interaction to form a transcriptionally active p53 tetramer12.
In the tetrameric conformation, p53 utilizes its sequence specific DNA binding domain to
recognize p53 response element (p53RE) and is able to transactivate its target genes
(Figure 1.2C)9. In order to do this, it requires the domains shown in Figure 1.2, with
tetramerization being critical and the CTD regulating transactivation function. The genes
that are transcribed to aid the role of p53 in maintaining genomic stability are many, some
notable examples include p21, a cyclin-dependent kinase inhibitor which initiates cell

Figure
1.2:
Domain
activationinducer
of p53.
(A) BAX
TA= 9,10
Transactivation
cycle
arrest
in G1
when architecture
activated, andand
the apoptosis
protein
.
domain, PR= Proline rich region, DBD= DNA binding domain, OD= Oligomerization
domain and CTD= C-terminal domain (B) Regulation of TP53 in unstressed state. TP53
is ubiquitinated and marked for proteasomal degradation. (C) In stressed state, posttranslational modification results in stabilization and activation of p53 and the eventual
transactivation of its target genes. Adapted from Aubrey et al, Cell death and
differentiation 2017; Sabapathy and Lane Nature review Clinical oncology 2017.
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1.3 Mutations in TP53
Germline TP53 mutations in critical regions of the p53 gene are found in what is
termed an autosomal-dominant disorder called Li-Fraumeni syndrome (LFS). A strong
familial aggregation of cancer, early tumor onset, and wide tumor spectrum are major
characteristic of LFS10. The prevalent childhood cancers associated with germline TP53
mutation include cancers of the bone, brain, adrenal gland, and soft tissue19,20. A
population of adult females with germline TP53 mutation are reported to develop breast
cancer before they are 31 years old10. Germline TP53 mutations are passed on from
parents to offspring and occur in about 1 in 5000 births.
Sporadic mutations in TP53 are found in over 50% of all human tumors17. In
advanced stages of certain cancers (ovarian, esophageal, colorectal, head and neck, and
lung cancers) as well as in aggressive subtypes of breast cancers (triple negative or
HER2- amplified breast cancers), somatic TP53 mutations are very frequent11. TP53 is
often inactivated via alternative mechanisms in cancers with low TP53 mutation rates11.
These mutations result from environmental factors (such as smoking, and exposure to
radiations and other carcinogens) and affect the cells of the patients and are not passed
down to offspring.
A subset of gene mutations responsible for a majority of the observed TP53
mutation in cancers are missense mutations. In missense mutations, there is a change in
the nucleotides of a codon which eventually leads to the translation of a single amino acid
into a different amino acid. More than 70% of all mutations in TP53 in cancers are
missense mutations, with the rest of the predominant TP53 mutation being frameshift,
deletions, and nonsense mutations7 (Figure 1.3A). Data from the International Agency for
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Research on Cancer (IARC) shows that cancer patients with TP53 missense mutations
usually have mutations in the DNA binding domain (DBD)9,18. In the cancer patients
studied, when the frequency of missense mutations were compared, six positions had a
remarkably high frequency and were tagged as “hotspot’’ (R175, G245, R248, R249,
R273 and R282) mutants7. Germline and somatic TP53 mutations have relatively similar
hotspot mutations in the DNA binding domain (DBD). In LFS patients, there are some
additional mutations in the OD of TP53 which are not prevalent in the somatic
mutations18,21. One of such missense mutation is the R337 mutation which has been
found in a cohort in Brazil to be implicated in adrenocortical carcinomas12 (Figure 1.3B).
During the early stages of mtp53 associated cancer development, it has been
suggested that missense mutations in one allele of TP53 prevent wtp53 from forming a
transcriptionally active homo-tetramer13. Instead, in a process known as dominantnegative effect, wtp53 forms a transcriptionally inactive mixed oligomer with mtp537,10.
The concept of dominant negative effect has been explored experimentally by cotransfecting wtp53 and mtp53 expressing plasmid in a p53 -/- background. There is a
significant decrease in the ability of wtp53 to bind to DNA and transactivate (increase the
transcription of) its target genes in the presence of mtp5314,15. In most mtp53 expressing
cancer cells, the wild-type allele is completely lost, leaving behind only a mutant allele.
The singular presence of this mtp53 allele makes the gene appear homozygous,
described as loss of heterozygosity (LOH)8,22. Based on the type of amino acid
substitution that occurs in the hotspot mutants, they are broadly described as either
structural/conformation mutants (G245S, R249S, R282H, and R175H) or contact mutants
(R248W, R248Q, and R273H). The structural/conformation mutants indirectly affect the
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DNA-binding capacity of mtp53 by altering the protein folding, which compromise the
protein structure while the contact mutants directly compromise the ability of the DBD to
interact with DNA25.

Figure 1.3: Mutation distribution in TP53. (A) A pie chart representation of the types
of mutations predominant in the TP53 gene. Missense mutation is the highest mutation
in TP53. Mutations in TP53 leads to the loss of the tumor suppressor function of TP53
(B) A graphical representation of the mutational frequency of TP53 in somatic and
germline cells. Most hotspot mutations are localized to the DBD of TP53. Adapted from
Brosh and Rotter Nature review Cancer 2009; Sabapathy and Lane Nature review
Clinical oncology 2017.
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1.4.a Gain-Of-Function (GOF) Mutant p53 Activities
The biochemical basis for wtp53 to function as a tumor suppressor is predicated
on the ability of the DBD of p53 to bind specific consensus sequence in the p53 Response
Element of the target gene16-19. In the early 90’s Bargonetti et al used the electrophoretic
mobility shift assay (EMSA) to show that wtp53 is able to bind specific DNA sequences.
However, the ability of wtp53 to bind specific DNA sequence was inhibited by SV40 T
antigen or mtp5320,21. The ability of wtp53 to function as a tumor suppressor is
compromised by mutations within the TP53 gene. These mutation leads to the loss-offunction phenotype of some mtp53. The TP53 mutations, which lead to loss of wtp53
tumor suppressor activity are mostly deletion and truncation mutations (which lead to
lack/reduced expression of the p53 protein), as well as missense TP53 mutations (which
lead to translation into a different amino acid which reduce the activity of p53). The
biochemical basis for the observed loss-of-function of mtp53 is based on experiments
using EMSA (which showed a shift in mobility comparing a wtp53 to a mtp53 binding to a
specific DNA sequence), as well as glutaraldehyde crosslinking assay which showed a
variation in the predominant oligomerization form of p53 when a wtp53 is compared to
different forms of mtp5317,22,23. This decreased DNA binding ability and altered
predominant p53 conformation resulted in the reduced ability of p53 to transactivate its
target genes.
Other missense mtp53 described as hotspot mutants, acquire neo-morphic
abilities described as Gain-Of-Function (GOF). These mutants have longer half-lives,
ability to activate the transcription of non-canonical genes in ways that utilize other
transcription factors, and interactions with oncogenic proteins to enhance their
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tumorigenicity9,23. The GOF oncogenic abilities of mtp53 were uncovered in part by
research in which overexpression of specific hotspot mtp53; R175H, R248W, R273H, and
R281G in p53 null cells resulted in a profound oncogene cooperation for cellular growth
in soft agar as well as enhanced tumorigenicity when the cells were implanted into nude
mice24. Follow-up research reported that cancer cells tend to be addicted to mtp53 for
their survival and thus become less viable when mtp53 is depleted25,26.
The GOF mtp53 phenotype observed in vitro by overexpressing mtp53 in p53 null
cells or in cell lines homozygous for mtp53 was confirmed in vivo by generating mutant
Tp53-knock-in mice. For the duration of the experiment, mice expressing wtp53 did not
form sporadic tumors and were tumor free. Tp53-knock-in mice expressing different LOF
mutations were not tumor free but formed tumors to a similar extent. Homozygous GOF
mtp53 expressing mice on the other hand formed sporadic tumors rapidly leading to the
early death of those mice27,28 (Figure 1.4A).
1.4.b The Oligomerization Domain and GOF mtp53
The OD of p53 is comprised of amino acid residues that stretch from position 323355. The monomeric composition of the OD is a ß-strand (Glu326-Arg333), a tight turn
(Gly334), and an α-helix (Arg335-Gly355)9,10. Two monomeric ODs form a dimer when
their ß-strands interact in an anti-parallel manner27. This anti-parallel ß-strand interaction
allows each dimer to have its α-helix sticking out, in a way that allows it to interact as a
dimer-of-dimer with other α-helices to form a four-helix tetramer10,27 (Figure 1.4B). This
four-helix tetramer configuration positions the DBD in close proximity to the p53 response
element (p53RE) allowing the DBD to interact easily with the p53RE10,27. The OD also
acts as a spot for post-translational modification and protein-protein interaction which
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regulates tetramer formation and the overall functionality of the OD29. Amino acid residues
at positions 333, 335, and 337 are frequently methylated, 340 is oxidized, 327 is nitrated
and 351, 357 ubiquitinated29.
Experiments using recombinant mtp53 from LFS patients harboring OD mutations
showed that OD associated mutations destabilize p53 tetramer formation. The sequence
specific DNA binding ability of wtp53 is reduced in the OD specific mutants as well as a
decrease in the ability to upregulate the expression of canonical targets p21 and BCL2
Associated X (Bax)28–30. When a peptide with sequence similarity to the OD of wtp53 was
designed, treatment of wtp53 expressing cells with this peptide led to a decrease in the
ability of wtp53 to transactivate p2129. These and other observations stress the
importance of the oligomerization state of p53 to wtp53 tumor suppressor functions.
1.4.c The C-terminal Domain and GOF mtp53
The CTD of p53 is comprised of amino acids stretching from position 364-393. It
is regarded as the regulatory domain of the p53 protein and called the basic domain
because of the abundance of lysine residues in the domain. Unlike the DBD and OD of
p53, the CTD doesn’t have an associated 3D structure. As such, it is said to be an
Intrinsically Disordered Region (IDR). IDRs are a class of polypeptide which demonstrate
a broad range of conformational dynamics due to the absence of 3D structural
constraints30. As an IDR, the CTD is able to mediate a variety of activities that enable the
p53 protein to carry out its function. Because the CTD is rich in lysine, the positively
charged lysine enables the CTD to associate with the negatively charged phosphate
backbone of DNA in a non-sequence specific manner. It also allows the domain to fold
back over the other regions of p53 and inhibit some site-specific DNA binding
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functions30,31. Gradual deletion of the lysine residues results in an abrogation of DNA
binding to the CTD in vitro32. However, in vivo mice work showed the outcomes vary from
tissue to tissue. In some tissues there is upregulation of p53 target genes whiles in others
there is downregulation of p53 target genes upon CTD residue deletions33 . The CTD
also acts as the site for a variety of post-translational modifications such as
phosphorylation, acetylation, ubiquitination, methylation, and SUMOylating as well as
allowing for protein-protein interaction30,31.
One such protein p53 interacts with is Poly-ADP Ribose Polymerase (PARP). PolyADP-ribose polymerase (PARP1) is an enzyme that adds Poly-ADP-ribose (PAR) chains
to single strand breaks in DNA and marks them for repair. PARP auto-PARylates itself
and a strong interaction has been found between PARylated PARP and the C-terminus
of p5334. A point mutation that changes the lysine residues to arginine residues in the
CTD of p53 has been found to block its interaction with PAR8,34. However, how mtp53
interact with PARylated PARP has not yet been elucidated. The Bargonetti lab
established a mutant p53-MCM2-PARP1 axis on the chromatin and discovered that in
two GOF mtp53 proteins, R273H and R248Q, PARP1 was recruited to the chromatin in
a mtp53 dependent manner 35,36 (Figure 1.4C).
Transcription Independent GOF activities of mtp53
The GOF mtp53 activity has also been identified to occur by activities that are
transcription-independent. Our group and others have reported a host of transcription
independent mtp53 GOF activities that associate with the ability of mtp53 to interact tightly
with chromatin in a non-sequence specific binding manner. The OD and CTD have been
reported as sites for a variety of protein-protein interactions, non-specific DNA binding
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activity, and protein post-translational modification29,37. In relation to DNA replication
mechanisms, we reported that mtp53 associates with replicating DNA in the presence of
PARP138. Protein kinase B (Akt) phosphorylates topoisomerase IIß binding protein
(TopBP1) to induce its oligomerization. This event inhibits the ATR-activation function of
TopBP139. Liu et al,. reported that in response to replication stress, both contact (R273H)
and conformational (R175H) mtp53 binds to TopBP1 to attenuate ATR checkpoint
response (bypassing the need of Akt in this process). Also, DNA contact mtp53 facilitates
the TopBP1/Treslin interaction to override Cdk2 requirement in promoting replication
during normal growth39.
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Figure 1.4: Gain-Of-Function activity of mtp53 and structural depiction of the OD
and CTD of TP53. (A) A tumor-free survival curve representation of how GOF mtp53
elicit tumor formation to a higher degree compared to various LOF mutants. (B)
Representation of how the OD aids in the formation of a transcriptionally active tetramer
conformation for TP53 activity. The residues depicted in red help the protein to form a
dimer whiles those in green help in tetramer formation. (C) Focus on the regulatory CTD,
involved in non-specific DNA binding and main site for post-translational modification.
The yellow color depicts intrinsically disordered regions. Adapted from Sabapathy and
Lane Nature review Clinical oncology 2017; Lozano et al., Genesdev 2020 and Laptenko
et al., Trends in Biochemical Sciences 2016).
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1.5 Purpose of Proposed Study
Most mutations, including those that disrupt the sequence specific DNA binding
activity of wild-type p53 (wtp53), result in loss of p53 tumor suppressor function. A subset
of TP53 mutations transform the gene into an oncogene producing a class of mutant p53
(mtp53) proteins called Gain-Of-Function (GOF) mutants. The GOF mtp53 proteins
possess biochemical properties distinct from wtp53.
The OD and CTD have been found to play critical roles in the tumor suppressive
function of wtp53. Generation of cell lines expressing mutations within the OD and CTD
compromised wtp53 activity12,30,31,33,40,41. Destabilizing tetramer formation by introducing
point mutations within the OD led to a reduction in DNA binding and decreased the ability
of p53 to activate transcription of p21 and Bax22,23. Studies in which plasmids expressing
GOF mtp53 (R175H and R273H) were transiently transfected into human cells showed
an upregulation of the DNA replicating factor Cell division cycle 7 (CDC7), a regulator of
DNA replication. Upregulation of CDC7 controls the increase in DNA replication origin
firing observed in cells with GOF mtp5342. Tumor suppressor function of wtp53 relating to
its ability to bind DNA and activate transcription of target genes has also been found to
be decreased when residues in the CTD, particularly lysines, are deleted31. However,
mouse models also show activation of transcription of p53 target genes in certain tissues
when the CTD is deleted33,40
We discovered an association between GOF mtp53 R273H, the DNA damage
signaling protein Poly-ADP ribose polymerase (PARP1) and the DNA helicase mini
chromosome maintenance complex (MCM2-7) on chromatin which we call the mtp53-
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PARP-MCM axis. We further confirmed the presence of mtp53 and PARP1 on replicating
DNA which supports a role for GOF mtp53 in DNA repair and/or replication mechanisms.
All GOF mtp53 studied thus far maintain an intact OD and CTD, suggesting a possible
role of the OD and/or CTD in their GOF activities. What hasn’t been explored to date is
how the OD and CTD of mtp53 affected its oncogenic GOF activities.
1.5.1 Research Question and Hypothesis
For this reason, we addressed the question of whether the OD and CTD were
critical for transcription-independent GOF mtp53 oncogenic activities. The central
hypothesis for this project is that an intact CTD and a tetrameric mtp53 conformation
regulate the oncogenic GOF activities of mtp53. Whilst there is strong scientific evidence
in support of this hypothesis with respect to wtp53, the mechanistic underpinning of how
the OD and CTD contribute to the mtp53 GOF activity is yet to be elucidated. To test this
hypothesis, we proposed the following specific aims.
1.5.2.a Specific Aim 1:
Elucidate the role of the mtp53 OD on GOF transcriptional activity
GOF mtp53 has been reported to upregulate the expression of non-canonical p53
target genes both in plasmids expressing different hotspot mtp53 as well as cells lines
expressing endogenous hotspot mtp53. Tetramerization is critical for the transactivation
of wtp53 target, a significant downregulation in expression is observed in wtp53 lines with
mutations introduced in the OD. Here, we will test the role of OD mutations in GOF mtp53
transcription-dependent activities. We will conduct experiments in exogenously
expressed GOF mutants R273H harboring OD mutations R337C, A347D. or L344P
(which destabilize p53 tetramerization) expressed in p53 -/- cancer cells.
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1.5.2.b Specific Aim 2:
Examine the role of mtp53 OD on protein association with replicating DNA
We have shown that GOF mtp53 associates with replicating DNA. We will test the
role of the OD and CTD in influencing the association of cancer cells expressing R273H
GOF mtp53 with nascent DNA and chromatin associated replication factors. We will
compare the difference in chromatin and nascent DNA association between cancer cells
expressing R273H GOF mtp53 to cancer cells expressing R273H GOF mtp53 with
deletions within the OD and CTD to assess how these regions regulate mtp53 GOF
activities.
1.5.2.b Specific Aim 3:
Examining how deletion of the CTD and portions of the OD of mtp53 affect in vivo
tumor formation
We recently showed that MDA-MB-468 cells expressing mtp53 R273H GOF with
a CRISPR/Cas9 mediated deletion of the entire CTD of mtp53 proliferate slowly, and
progress slowly through the cell cycle. This suggests that the CTD is critical for the
oncogenic high proliferation of R273H parental cells. We will be testing whether the
observed slowed proliferation and cell cycle progression will affect tumor development in
vivo.
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2.1 ABSTRACT
The TP53 gene is often mutated in cancer, with missense mutations found in the central
DNA binding domain, and less often in the C-terminal oligomerization domain (OD).
These types of mutations are found in patients with the rare inherited cancer
predisposition disorder called Li-Fraumeni syndrome. We previously found that mutant
p53 (mtp53) R273H associates with replicating DNA and promotes the chromatin
association of replication-associated proteins mini-chromosome maintenance 2 (MCM2),
and poly ADP-ribose polymerase 1(PARP1). Herein, we created dual mutants in order to
test if the oligomerization state of mtp53 R273H played a role in chromatin binding
oncogenic gain-of-function (GOF) activities. We used site-directed mutagenesis to
introduce point mutations in the OD in wild-type p53 (wtp53), and mtp53 R273H
expressing plasmids. The glutaraldehyde crosslinking assay revealed that both wtp53
and mtp53 R273H formed predominantly tetramers, while the single OD mutant A347D,
and the dual mtp53 R273H-A347D, formed predominantly dimers. The single OD mutants
R337C, L344P, and the dual mtp53 R273H-R337C, and mtp53 R273H-L344P proteins
formed predominantly monomers. Wtp53 was able to activate transcription of the cyclindependent kinase gene p21/waf and the p53 feedback regulator MDM2. As expected, the
transactivation activity was lost for all the single mutants, as well as the mtp53 R273Hdual mutants. Importantly, mtp53 R273H and the dual oligomerization mutants, R273HA347D, R273H-R337C, and R273H-L344P were able to interact with chromatin.
Additionally, the dual oligomerization mutants, R273H-A347D, R273H-R337C, and
R273H-L344P, maintained strong interactions with MCM2 and PARP1. Our findings
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suggest that while mtp53 R273H can form tetramers, tetramer formation is not required
for the GOF associated chromatin interactions.
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2.2 INTRODUCTION
Cancers often have genetic mutations in the TP53 gene that can be both inherited
and spontaneous43. These mutations often disrupt the sequence-specific DNA binding
activity of wild-type p53 (wtp53) and can also be found, albeit less frequently, in the Cterminal oligomerization domain (OD) 43. A subset of TP53 mutations transform the gene
into an oncogene, producing a class of mutant p53 (mtp53) proteins known to have gainof-function (GOF) properties that help in tumor promotion 16,44. The GOF mtp53 proteins
possess biochemical properties distinct from wtp53, including longer half-lives,
transcriptional activation of non-canonical p53 target genes, and exhibit stable complex
formation with both canonical and non-canonical protein interaction partners 13,27. Amino
acids in the central region of wild-type p53 form direct DNA contacts and conformationally
coordinate the protein for stable sequence-specific interactions at p53 response
elements; the hotspot cancer amino acid mutations in Arg 248 (R248) and Arg 273 (R273)
correspond to amino acid residues that make direct contact with the DNA backbone

45

.

The fact that p53 functions as a tetramer was discovered in part by glutaraldehyde crosslinking experiments that examined the entire protein
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. Crystal structure studies

exclusively with the OD further clarified how critical p53 amino acids affect tetramer
formation 46,47.
The OD of p53 is composed of amino acid residues stretching from position 323355 that assist in sequence specific DNA binding and transcriptional activation

48

. The

OD of p53 is comprised of a ß-strand (Glu326-Arg333), a tight turn (Gly334), and an αhelix (Arg335-Gly355)

47,49

. Two monomeric p53s form a dimer when the ß-strands of

their ODs interact in an anti-parallel manner. This anti-parallel ß-strand-interaction allows
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each dimer to have its α-helix projecting outward, allowing it to form a dimer-of-dimers
with other α-helices to form a four-helix tetramer 41. The four-helix tetramer configuration
positions the DNA-binding domain close to the p53 response element for easy interaction
and is required for transactivation of target genes 28,44.
Tetramerization of wtp53 is important for tumor-suppressor activities that lead to
the activation of apoptosis

50

. Compromising the ability of wtp53 to form a tetramer

downregulates the expression of p53 target genes
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. In Li-Fraumeni syndrome (a

condition where patients present with germline p53 mutations and have a predisposition
to early-life cancer development), point mutations within the OD (R337C, A347D, or
L344P) destabilize tetramer formation and decrease the ability of p53 to bind DNA, as
well as activate transcription of p21, Bax, and p53 upregulated modulator of apoptosis
(PUMA)

12,23,47

. Interestingly, in cancers the p53 associated mutations have never been

reported to occur simultaneously in the OD and in the DNA binding domain. This suggests
that the OD and DNA binding domain mutations make independent contributions to p53
transactivation activity. Therefore, there is no selection for dual mutants in cancers.
Simply inhibiting the transcription factor function of p53, in one way or the other, would
be enough to promote tumorigenesis. However, p53 is known to have functions that are
separable from its transcription factor activity. For example. p53 participates in the
regulation of DNA replication 8. It may be some of these functions that are co-opted by
different GOF mtp53 proteins. Recently, a C-terminal frame shift p53 mutant has been
shown to gain some new functions
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. We found that mtp53 R273H associates with

replicating chromatin, but it was not clear if the oligomerization of mtp53 played a role in
chromatin-association
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. With this in mind, we decided to create dual mutants (even
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though these do not exist in cancers). This was done in order to investigate whether the
oligomerization state of mtp53 R273H influenced the DNA binding of mtp53 R273H, and
the GOF associated replication activities.
GOF mtp53 R273H interacts with replicating DNA, and the replication associated
proteins poly ADP-ribose polymerase 1 (PARP1), and the DNA helicase minichromosome maintenance complex (MCM2-7) in a mtp53-PARP-MCM axis 8,35,38,53. The
mtp53-PARP-MCM axis on chromatin suggests a role for GOF mtp53 in DNA repair
and/or replication mechanisms. Exogenous expression of GOF mtp53 (R175H or R273H)
in human cells correlates with the increased transcription of DNA replicating factor CDC7
(which increases DNA replication origin firing)

42

. The transcriptional activation of

previously silent genes in the presence of mtp53 in cancer cells has recently been
associated with p53 mutations driving aneuploidy, rather than as a direct transcriptional
response 54.
Li-Fraumeni syndrome (LFS) predisposes patients to early onset of different types
of cancer 55-57. In a cohort in Brazil, it was reported that the R337C mutation in the OD of
p53 predisposes LFS patients to adenocarcinoma 58. While it has already been reported
that mutations in the OD region compromise wtp53 transcriptional activity, we wanted to
determine if LFS associated OD mutations changed mtp53 R273H chromatin-associated
activities. We used site-directed mutagenesis to introduce point mutations in plasmids
expressing either wtp53 or mtp53 R273H to alter amino acids R337C, A347D, and L344P.
We observed that exogenously expressed mtp53 R273H formed tetramers, and that dual
mtp53 R273H-A347D formed predominantly dimers, while dual mtp53 R273H-R337C
and R273H-L344P formed predominantly monomers. The destabilizing oligomerization
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mutations to create dual-mtp53 did not inhibit mtp53 R273H interactions with chromatin.
Moreover, the interaction between mtp53 R273H and MCM2 or PARP1 were maintained
in the dual-R273H oligomerization mutants. These findings suggest that oligomerization
of GOF mtp53 R273H does not significantly influence GOF chromatin associated
activities.
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2.3 Materials and methods
2.3.1 Materials
Solvents and chemicals including DMSO, glutaraldehyde, temozolomide, and
talazoparib were obtained from Sigma-Aldrich (St. Louis, MO, USA). DO1 p53 (Cat# sc126) monoclonal and PARP1 (Cat# sc-7150) rabbit polyclonal antibodies were
purchased from Santa Cruz (USA). MCM2 (Cat# 12079s) mouse antibody was
purchased from Cell Signaling Technology. An Eppendorf 5415 refrigerated centrifuge
was used for preparation of all extracts.

2.3.2 Cell culture and drug treatments
Human breast cancer cell line MDA-MB-468 was purchased from ATCC (www.atcc.org)
and the HCT116 colon cancer cell line that is p53-/- was a gift from Bert Vogelstein and
were made as described

59,60

. Cell lines were regularly authenticated via short tandem

repeat technology (Genetica DNA Laboratories). Cells were routinely checked for
mycoplasma contamination by PCR assay (ATCC). Fresh cells were thawed when the
passaging period was around 30. Cells were maintained at 5% CO2 in a 37°C humidified
incubator. HCT116 p53-/- and MDA-MB-468 cells were cultured in McCoy’s 5A (Gibco)
and DMEM media (Corning) respectively, with 50 U/ml penicillin, 50 μg/ml streptomycin
(Mediatech), 5 ug/ml plasmocin (InvivoGen) and supplemented with 10% FBS (Gemini).
PARP-dependent recruitment of proteins to chromatin was assayed by exposure of
HCT116 cells to 1 mM Temozolomide (Sigma-Aldrich; 100 mM stock solution in DMSO)
and 10 µM Talazoparib (Selleckchem; 20 mM stock solution in DMSO) combination
treatment for 4 hr. at 37°C followed by chromatin isolation as described 35.
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2.3.3 Site-directed mutagenesis, clone validation, and transfection
To generate clones expressing p53 with the desired mutations in the oligomerization
domain, we used the Nebasechanger (https://nebasechanger.neb.com) platform to
design primers to introduce specific point mutations within the OD of pCMV-FLAG-wtp53
40

. For

and

R:

and pCMV-FLAG-p53R273H plasmids which express wtp53 or R273H mtp53
R337C,

the

primer

pair

was

F:

TGGGCGTGAGtGCTTCGAGAT

CGGATCTGAAGGGTGAAATATTCTC (annealing temperature 66oC). For A347D, the
primer

pair

was

F:

CTGAATGAGGaCTTGGAACTC

and

R:

CTCTCGGAACATCTCGAAG (annealing temperature 62oC). Lastly, for L344P the primer
pair was F: TTCCGAGAGCcGAATGAGGCC and R: CATCTCGAAGCGCTCACG
(annealing temperature 65oC). A PCR reaction was set up with CMV-wtp53 or CMVR273H plasmid template and the Q5 Hotstart high-fidelity 2X master mix (NEB) at the
specific annealing temperature of each primer pair. After confirming PCR amplicon with
agarose gel electrophoresis, a kinase-ligase-Dpn1 (NEB) reaction was done before
transforming DH5α competent cells. DNA was isolated from cultured transformants
(grown in LB+50µg/ml Amp) using the Qiagen miniprep/midiprep kit, sequenced
(Genewiz) using a p53 Exon 8 F primer 5’ ACAGCACATGACGGAGGTTGT, and
plasmids harboring mutations were confirmed using the BenchlingTM platform.
Sequences were compared to TP53 cDNA from the GRCh38 homo sapiens reference
genome using the benchling platform’s external databases. Plasmids with the desired OD
mutations were transfected into HCT116 p53-/- cells using either the lipofectamineTM
(Invitrogen) or the electroporation-based Neon Transfection System TM (Thermofisher) as
directed by the manufacturers. For the nucleofection, the transfection protocol as
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previously described for MDA-MB-468 cells was followed with little modification

61

. The

conditions for introduction of plasmids into HCT116 p53-/- cells (7 µg/1,000,000 cells)
using the Neon were pulsation 1x for 20 ms at 1530 V followed by culturing in McCoy’s
5A media + 10% FBS without antibiotics.
2.3.4 Glutaraldehyde chemical cross-linking assay
This assay was carried out as described previously for MDA-MB-468 cells and purified
R273H mtp53

61,62

. Cells were harvested by washing with cold PBS, harvested by

scraping in cold PBS, and centrifuging at 1,400 g (1100 rpm) for 7 min. Harvested cells
were lysed with phosphate lysis buffer (1x PBS, 10% glycerol, 10 mMEDTA, 0.5% NP40, 0.1M KCl, 1 mM PMSF, 8.5 μg/mL aprotinin, 2 μg/mL leupeptin, and phosphatase
inhibitor cocktail). A total of 50 μg of protein lysates were treated without, or with,
glutaraldehyde at a final concentration of 0.005%. The lysates were then incubated at
room temperature for 20 min on a shaker. The crosslinking was stopped by the addition
of 1/6 of the volume with 6X protein sample buffer (6X SDS Laemmli sample buffer, 0.2
M DTT) and heated at 95oC for 10 min. 25 μg (1x10^6 cells)was resolved on an 8% SDSPAGE gel and Western blot analysis was performed with DO1 p53 monoclonal antibody.
2.3.5 TaqMan real-time PCR
Total RNA was isolated from cell cultures as dictated by the experimental design using
the Qiagen RNeasyTM kit as directed by the manufacturers (www.qiagen.com/HB-0435).
The Applied Biosystems High-Capacity cDNA Reverse Transcription kit was used to
generate cDNA from 5 μg of total RNA from each cell sample. The relative abundance of
the TP53, cyclin dependent kinase inhibitor (p21), MDM2, Ribonucleotide Reductase
Membrane subunit 2 (RRM2) and cell division cycle 7 (CDC7) mRNA within each cell was
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measured by quantitative-PCR using the Applied Biosystems TaqMan real-time
PCR with FAM dye-labeled probes and GAPDH as an endogenous control (Thermofisher
Scientific TP53 ID# 01034249_m1, p21 cat# 4331182, MDM2 cat# 4351372 RRM2 cat#
01072069_g1, CDC7 ID# 00177487_m1, and GAPDH ID# 02786624_g1) and the
Applied Biosystems QuantStudio 7 Flex instrument.
2.3.6 Whole-cell lysis and Immunoblotting assay
Cells were harvested by low-speed centrifugation at 1,400 g (1100 rpm) for 7 min at 4°C.
Cells were washed three times with ice-cold PBS and resuspended in RIPA buffer (0.1%
SDS, 1% IGEPAL NP-40, 0.5% Deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 50 mM Tris-Cl pH 8.0, 1 mM PMSF, 8.5 µg/ml Aprotinin, 2 µg/ml Leupeptin and
phosphatase inhibitor cocktail). The cell suspension was incubated on ice for 30 min to
lyse the cells, with gentle vortexing every 5 min., after which, lysates were subject to
sonication 3x for 30 sec pulses/ 30 sec rest on ice at 98% amplitude and then centrifuged
at 15,700 g (13,200 rpm) for 30 min at 4°C. The protein concentrations of clarified cell
extracts were determined using the Bradford assay (Bio-Rad), and 50 µg (1.5x10^6 cells)
of extracts was analyzed for specific proteins by electro-transfer onto Polyvinylidene
fluoride membrane (Amersham-GE Biosciences) following SDS-PAGE. The membrane
was blocked with 5% non-fat milk (Bio-Rad) in either 1X PBS-0.1% Tween-20 or 1X TBS0.1% Tween-20 followed by an overnight incubation with primary antibody at 4°C. The
membrane was washed 3x with either 1X PBS-0.1% Tween-20 or 1X TBS-0.1% Tween20 and incubated with Cy5- and Cy3-linked secondary antibodies (Amersham
Biosciences) for 1hr at room temperature. The signal was detected with the Typhoon FLA
7000 laser scanner (GE Healthcare). Primary antibodies used were (1) anti-p53 DO1 p53
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(Santa Cruz Cat# sc-126), (2) anti-PARP1 (Santa Cruz Cat# sc-7150), (3) anti-MCM2
1E7 (Cell Signalling Technology Cat# 12079s).
2.3.7 Chromatin fractionation assay
Localization of mtp53 proteins to chromosomes was assessed using a version of the
Chromatin Fractionation Assay as described
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. Cells (2x10^6 cells) were harvested 24

hr post-transfection as dictated by experimental conditions by scraping, pelleted, and
washed with ice-cold PBS three times. The pellet was resuspended in Buffer A (10 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2, 300 mM Sucrose, 1mM DTT, 10% Glycerol, 0.1 mM
PMSF, 1 μg/ml Leupeptin, 1 μg/ml Pepstatin A, and 2 μg/ml Aprotinin) with 0.1% Triton
X-100 using 3X the pellet volume. The resuspended pellet was centrifuged at 1,500 g
(4,000 rpm) for 5 min after incubating on ice for 5 min. The resulting pellet containing
nuclei was saved and the supernatant spun at 15,700 g (13,200 rpm) for 5 min; the
supernatant from this centrifugation step was saved as S1. The nuclei from each sample
were washed twice in Buffer A + 0.15% Triton X-100 then lysed in Buffer B (3 mM EDTA,
0.2 mM EGTA, 1 mM DTT, 0.1 mM PMSF, 1 μg/ml Leupeptin, 1 μg/ml Pepstatin A, and
2 μg/ml Aprotinin) on ice for 30 min. The chromatin for each sample was separated from
the nuclear lysate (S2) by centrifugation for 4 min at 1,500 g (4,000 rpm) at 4°C, washed
with Buffer B, and then collected by centrifugation as described above. The chromatin
pellet was resuspended in Buffer B and sonicated on ice to shear genomic DNA, the
resulting solution was saved as the chromatin fraction. The protein concentrations were
measured using the Bradford assay (Bio-Rad). ImageJ quantification is shown in
Supplementary Figure 3A. The ImageJ software was used to determine the western blot
band intensity with signals normalized to their respective Lamin control. The relative

28

expression of p53 in the HCT116-/- transfected cells was determined by using the level
of R273H protein in the no drug treatment as the reference sample. The relative
expression of MCM2 and PARP1, was determine by using the protein levels in the empty
vector transfection sample with no drug treatment as the reference samples.
2.3.8 Detergent Solubility assay
The method was derived from a DNA repair tight tethering detergent assay 63. Transfected
HCT116 p53-/- cells (2x10^6 cells)were harvested and then stored at -80˚C. For
preparation of the soluble and insoluble fractions, the frozen cell pellets were lysed for 1
hr at 4°C in TNE (pH 8.0) buffer (50 mM Tris, pH8.0,120 mM NaCl, 1 mM EDTA, 0.5%
Nonidet P-40, 100 g/ml phenylmethylsulphonyl fluoride, 5 g/ml aprotinin, 5 g/ml Pepstatin,
2 g/ml leupeptin, 50 mM NaF, 2 mM Na₃VO₄·2H₂O (Sodium Orthovanadate)).
Approximately 3x the cell pellet volume of TNE buffer was used for lysis. The lysate was
divided into the soluble and insoluble fractions by centrifugation at 15,700 g (13,200 rpm)
for 10 min at 4˚C. The supernatant-soluble fraction was transferred to a new tube. The
remaining pellet, or insoluble fraction was resuspended in PBS containing 2% SDS (~5x
insoluble cell pellet volume) and then sonicated 3 times for 30 sec pulses/ 30 sec rest on
ice at 98% amplitude (QSonica, LLC Q700). The protein concentration for the soluble
fraction was measured using the Bradford assay, while the protein concentration of the
insoluble fraction was obtained by absorbance at 280 nm reading from Nanodrop
Spectrophotometer (high SDS made it difficult to do a Bradford assay). Samples were
analyzed by western blotting as described above. ImageJ quantification is shown in
Supplementary Figure 3B and determined as described above for chromatin fractionation
samples.
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2.3.9 Immunofluorescent Assay (IF) coupled Proximity Ligation Assay (PLA)
The protocol for the proximity ligation assay using the Sigma Aldrich Duolink KitTM (Cat #
DUO92008) was as described previously
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. Cells were seeded in a 12-well glass-

bottomed plate at 1x105 cells per well in complete McCoy 5A media supplemented with
10% FBS without antibiotics. After 24 hrs, 1.6 ug of plasmid DNA was added to each well
via the lipofectamine transfection system as described by the manufacturer. After 24 hr
post-transfection, the media was removed, and the cells were washed with cold PBS 3
times. The cells were then fixed in 4% formaldehyde for 15 min and permeabilized in
0.5% Triton X-100 for 10 min at room temperature. The Duolink In-situ Red Kit (Cat #
DUO92101) was used for the PLA. Blocking buffer was added to each well and incubated
in a humidified chamber at 37oC for 30 min. After aspirating the blocking buffer, primary
antibodies were added to each well and incubated in a humidified chamber overnight at
room temperature. Wash buffer A (cat # DUO82049) was used to wash the cells 3 times
for 5 min each. The PLA Plus/Minus secondary antibody probes were added to the wells
and incubated in a humidified chamber for 60 min at 37oC. After that, the cells were
washed 2 times with buffer A for 2 min each. The ligation step was performed for 30 min
incubation at 37oC, washed 2 times with buffer A and the amplification was done for 100
min at 37oC. The wells were washed with buffer B for 10 min and incubated with a FITClabelled secondary antibody to detect p53. After washing 3 times, mounting media
containing DAPI was added to each well, rocked for 15 min, and images were taken using
the Nikon A1 confocal microscope. Images obtained were processed with the Nikon NIS
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Element software, ImageJ and Cellprofiler. The foci/cell were plotted, and statistical
analysis was performed in GraphPad Prism 9.
2.3.10 Statistical analysis
Statistical analyses were performed using GraphPad Prism 9. Results are expressed as
mean + SEM. Statistical significance for hypothesis testing was performed by a one-way
ANOVA with multiple comparison. The following format was used to assign significance
based on P-value: **** represents a p-value ≤ 0.0001 and ns represent non-significant.
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2.4 RESULTS
2.4.1 p53 tetramer formation is destabilized by introducing mutations in the OD
We used site-directed mutagenesis to introduce oligomerization mutations to change p53
amino acid residues R337C, A347D, or L344P in plasmids for exogenous expression of
either wtp53 or mtp53 R273H. When the Li-Fraumeni OD-specific associated point
mutations were introduced individually, or as dual mutants within mtp53 R273H, they
destabilized tetramer formation (Figures 2.1A and 2.1B). The exogenously expressed
wtp53 and mtp53 R273H proteins predominantly formed dimers and tetramers when
0.005% glutaraldehyde was added (Figures 2.1A and 2.1B, lanes 1 and 2), whereas both
single A347D and dual R273H-A347D polypeptides shifted to form predominantly dimers
(Figure 1A and 1B, lanes 5 and 6). The Li-Fraumeni mutations R337C and L344P, as well
as the dual mutants R273H-R337C and R273H-L344P, were unable to form dimers or
tetramers (Figure 2.1A and 2.1B, lanes 3, 4, 7 and 8). We also confirmed that endogenous
mtp53 in many different human breast cancer cell lines formed tetramers (Supplementary
Figure S2.1). These data indicate that mtp53 can exist as tetramers in human cells, and
that we successfully disrupted mtp53 R273H oligomerization in the R273H R337C,
A347D, or L344P dual mutants.
2.4.2 Transactivation of p21 and MDM2 is activated by wtp53, but not mtp53 R273H,
or OD mutants
The p53 protein activates the transcription of the cyclin-dependent kinase p21 and the
p53 inhibitor MDM2

64,65

. We wanted to confirm that destabilization of wtp53

oligomerization blocked transactivation. We expressed the R337C, A347D, or L344P
single or dual mtp53 R273H in HCT116 p53-/- cells and observed significant TP53
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message and protein expression in all the transfection experiments (Figures 2.2A and
2.2B, compare empty vector (EV) to expression constructs as indicated). As expected,
upregulation of the endogenous targets p21 and MDM2 occurred in the presence of wtp53
expression (Figures 2.2C and 2.2D), and the LFS mutations blocked the ability of p53 to
transactivate p21 and MDM2 (Figures 2.2C and 2.2D). Equally as predictable, the mtp53
R273H mtp53 expression was unable to activate expression of p21 or MDM2, and dual
mutants were no different (Figures 2.2C and 2.2D). The mtp53 R273H has been shown
to activate transcriptional targets CDC7 and RRM2

42,66

. As such, we examined the

amount of mRNA and protein expression levels of these targets. We examined whether
mtp53 R273H, or the mtp53 R273H dual mutants, significantly upregulated the
expression of either CDC7 or RRM2 (Supplementary Figure S2.2). However, we did not
detect upregulation for these genes. This could be due to low transfection efficiency (30%
efficiency), or other variables that may have influenced mtp53 mediated transcription
effects.

2.4.3 Destabilizing oligomerization of mtp53 does not block mtp53 interaction with
chromatin
Endogenous mtp53 R273H, and other mtp53 proteins, tightly tether to chromatin 35,53. We
tested whether the tetramerization state of mtp53 was crucial for the mtp53 chromatin
association. We transiently transfected in mtp53 R273H without, and with, the OD
mutations. To further examine how dual mutants influenced chromatin interaction, we
treated cells with a combination of the alkylating agent temozolomide (Temo) and the
PARP1 trapping drug talazoparib (Tal) to induce replication stress and trap PARP1 on
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the chromatin

35,38

. We then isolated chromatin by either chromatin fractionation, or the

more stringent detergent insoluble fractionation assay, as methods to assess proteinDNA tethering. We observed mtp53 R273H and mtp53 R273H-dual oligomerization
mutants tightly tethered to chromatin (Figures 2.3A and 32.B, with ImageJ quantification
shown in Supplementary Figures S2.3A and S2.3B). The replication stress of Temo plus
Tal treatment did not significantly alter the ability of mtp53 to interact with chromatin
regardless of the OD domain status (Figures 2.3A and 3.2B, and Supplementary Figures
S2.3A and S2.B). We therefore conclude that oligomerization of mtp53 R273H is not
required for mtp53 chromatin association. Moreover, both PARP and MCM2 interacted
well with the chromatin in both unstressed and stressed conditions. The p53 protein that
cannot form tetramers does not activate gene transcription. However, the possibility exists
that monomers and dimers are able to maintain non-specific chromatin interactions. We
compared wtp53, with and without OD mutations, for their general chromatin interactions
by transfecting HCT116 p53 -/- cells with plasmids expressing wtp53 or the single OD
mutants. Western blot analysis of the chromatin fractionated samples demonstrated that
the different oligomerization forms tethered well to the chromatin. As such, mutation in
the OD of p53 disrupts transcription factor function but does not disrupt the ability of the
protein to generally interact with chromatin (Supplementary Figure S2.3C).

2.4.4 Destabilizing oligomerization of R273H mtp53 does not inhibit interaction
between mtp53 and MCM2
We tested if oligomerization influenced the interaction of mtp53 R273H with either MCM2
or PARP1 by using the proximity ligation assay (PLA), which was previously used to
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demonstrate their endogenous interactions 38. We used transfected HCT116 p53-/- cells
in order to compare the interactions with similar levels of exogenously expressed protein
for wtp53 and R273H mtp53 single and dual mutants. The expression of GFP was used
as a marker for cells expressing p53 and importantly PLA foci were only detected in p53
expressing cells. Previously we had detected a low number of PLA foci for wtp53 in an
endogenously expressing cell line. This was due to the fact that endogenous wtp53
protein is maintained at low levels in MCF7 cancer cells due to degradation by the E3
ubiquitin ligase MDM2 (Xiao et al 2020). Interestingly, when the expression level was the
same, we detected similar interaction levels between MCM2 with both wtp53 and mtp53
R273H (Figures 2.4A and 2.4B). In contrast, the dual mtp53 R273H-OD mutants
demonstrated slightly more MCM2-mtp53 associated foci (Figures 2.4A and 2.4B). The
interaction between mtp53 and PARP1 was also maintained after introducing mutations
to destabilize tetramer formation, with no observable increase for the dual mutants
(Figures 2.4C and 2.4D). This suggests that R273H hotspot mtp53 may interact with
replicating DNA in forms that are not tetrameric. We also assessed the single-OD mutants
and observed interactions between the single-OD p53 mutants and MCM2 as well as
PARP1 (Supplementary Figure S2.4). This further supports the possibility that nontetramerized p53 may function in alternative, non-transcription related, pathways that
mediate GOF activity.
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2.4.5 Deletion of the non-specific DNA binding domain of mtp53 decreases the
interaction between mtp53 R273H and MCM2.
Generation of R273H mtp53 deletions of a small portion of the C-terminus (R273HΔ381388) and a larger deletion removing some of the OD and all of the C-terminus
(R273HΔ347-393) in MDA-MB-468 cells causes replication stress 61. The larger deletion
R273HΔ347-393 dual mutant causes drastic inhibition of cell proliferation. As such, we
wondered if the entire deletion of the C-terminal non-specific DNA binding domain
R273HΔ347-393 inhibited the interaction of mtp53 R273H with the replication machinery.
We tested the interaction between mtp53 and MCM2 using the PLA method and observed
that R273HΔ347-393, but not the smaller deletion R273HΔ381-388, exhibited decreased
interaction with the MCM2 replication helicase (Figures 2.5A and 2.5B).

36

2.5 DISCUSSION
Wild-type p53 requires tetramerization to be a functional transcription factor but
oncogenic mtp53 does not act as a direct transcription factor. As such, it remains to be
determined what roles are played by the different oligomerization forms of oncogenic
mutant p53. The newly generated dual mutants have both a DNA binding domain
mutation and an oligomerization domain mutation. Dual mutants are not naturally
occurring in cancers. Mutations in the OD that disrupt p53 transcription factor function
may allow for p53 functions (that to date have not been discovered and/or described) to
be co-opted in the mutant p53 isoforms. It is possible that monomers of p53 may have a
transcription-independent chromatin associated function, and our work may provide clues
for how equilibrium between different p53 oligomerization forms influence different cellular
functions. The observation of altered tumor-suppressor function resulting from LFS
mutations within the OD is similar to that observed in hotspot DNA binding domain
mutants 43. Both types of mutations lead to a loss of function for wtp53 tumor suppressor
functions. In the resulting cancers high levels of stable mtp53 occur 67. We have explored
how dual region mutations, in both the DNA binding domain and OD, influence the mtp53
replication-associated chromatin functions. We were able to change the oligomerization
state of mtp53 R273H such that the R273H-dual mutants possessed similar
oligomerization to their corresponding single LFS mutants (Figure 2.1).
The LFS mutations R337C, A347D, and L344P within the OD as expected blocked
the transactivation of wtp53 (Figure 2.2). The DNA binding domain mutation R273H
compromised the ability of the protein to activate transcription from endogenous p53
responsive elements. In the case of the mtp53 R273H-dual mutants, the presence of an
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extra mutation that prevented tetramer formation, not surprisingly, had no influence on
the transactivation ability (Figure 2.2). We did not observe mtp53 R273H mediated
transactivation of either CDC7 or RRM2 (Supplementary Figure S2.2). This supports the
recent finding that outcomes on activation of new genes may result from aneuploidy and
are not direct results of mtp53 R273H transactivation 54.
Chromatin tethering of mtp53 has implications in DNA replication and repair
mechanisms. Prior to this study, various reports confirmed that most of the chromatin
association of wtp53 occurs as a tetramer 18,19,68. We observed that hotspot GOF mtp53
R273H can form tetramers in cancer cell lines (Supplementary Figure S2.1) but that
tetramerization is not required for chromatin interaction, or interaction with MCM2
(Figures 2.3 and 2.4). The DNA replication machinery is under the regulation of protein
complexes that control origin licensing, firing, unwinding, and relaxation

69

. GOF mtp53

has been implicated in a variety of DNA replication processes, including an increase in
replication origin firing and enabling the interaction between TopBP1 with Treslin to
induce Cdk2 66,70. We previously reported a close association between mtp53, replicating
DNA, and PARP1
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. Herein, we explored whether the oligomerization of mtp53 R273H

was required for it to interact with PARP1, and the replication helicase MCM2. Our results
suggest that the interaction between mtp53 R273H and PARP is not significantly altered
by destabilizing mtp53 tetramer formation. On the other hand, there was a slight increase
in the interaction between mtp53 R273H-dual OD mutants and MCM2 (Figure 2.4). This
suggests that non-tetrameric forms of p53 may interact more often with the DNA
replication machinery. Interestingly, the absence of the entire C-terminal domain (which
is involved in non-specific DNA binding and nuclear localization) in the R273HΔ347-393
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mutant
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, had a reduced interaction with MCM2 (Figure 2.5). Taken together, the data

presented here showed that oncogenic mtp53 R273H can form tetramers, but that the
dynamics of tetramer formation and the C-terminal non-specific DNA binding domain may
differentially regulate the GOF replication-associated activities. We are in the process of
carrying out further experiments to explore how destabilizing tetramer formation and nonspecific DNA binding influence the association between mtp53 R273H and replicating
DNA.
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2.10 Figures and Legends

Figure 2.1: R273H-dual mtp53 mutants destabilize oligomerization of mtp53
R273H similar to Li-Fraumeni Syndrome single mutants. HCT116 p53-/- cells were
transiently transfected with plasmids expressing either (A) wtp53, or single mutants
R337C, A347D or L344P; or (B) mtp53 R273H, or dual mutants R273H-R337C, R273HA347D, or R273H-L344P. After 24 hr post transfection, cells were pelleted, and lysate
prepared. 50 μg of the resulting cell lysates were treated with either 0% (lanes 1,3,5,7)
or 0.005% (lanes 2,4,6,8) glutaraldehyde for 20 min at room temperature. Samples were
run on an 8% SDS-PAGE and oligomerization determined by western blotting using
anti-p53 DO1 antibody. Actin was used as a normalizer and showed very minor shift in
mobility with 0.005% glutaraldehyde. Data presented was reproduced in 3 biological
replicates.
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Figure 2.2: Both p21 and MDM2 are transactivated by wtp53 but not mtp53.
HCT116 p53-/- cells transfected with plasmids expressing wtp53, or single mutants
R337C, A347D or L344P; or mtp53 R273H, or dual mutants R273H-R337C, R273HA347D, or R273H-L344P were harvested 24 hr post-transfection. The pellets were
divided into two and used for either protein or RNA extraction. RNA was extracted
from pellet and 5 μg of RNA used for cDNA synthesis. The TaqMan real-time PCR
was used to measure the mRNA expression levels of p53 (A), p21 (C) and MDM2 (D)
target genes using GAPDH as endogenous control. The data represent an average of
3 independent biological replicates. A one-way ANOVA was used to determine the
statistical significance of the data. The following format was used to assign
significance based on P-value: **** represents a p-value ≤ 0.0001 and ns represent
non-significant. (B) Pellets were lysed in RIPA buffer and 25 μg of lysate loaded on a
10% SDS-PAGE and probed with anti-p53 DO1 antibody. Actin was used as a
normalizer. Data represent 3 independent biological replicates.
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Figure 2.3: Destabilizing oligomerization of mtp53 R273H does not block the
interaction with chromatin. The chromatin fractionation and the detergent solubility
assays were used to fractionate lysates prepared from HCT116 p53-/- cells transfected
with mtp53 R273H, or dual mutants R273H-R337C, R273H-A347D, or R273H-L344P
into cytosolic/soluble fraction and chromatin/insoluble fraction. Analysis of lysates from
cells without drug treatment (lanes 1,3,5,7,9) or with a combination of temozolomide (T)
at 1 mmol/L plus talazoparib (T) at 10 μmol/L for 4hr (lanes 2,4,6,8,10) was carried out.
Binding of mtp53, MCM2, and PARP1 to chromatin isolated from partially purified lysed
nuclei (chromatin fractionation assay) or high detergent total cell lysates (detergent
solubility assay) was assessed by western blot analysis. 25 μg of chromatin protein was
loaded on 10% SDS-PAGE gel. (A) Western blot depicting the chromatin association of
p53, MCM2, and PARP1 after chromatin fractionation. (B) Western blot analysis
depicting the chromatin association of p53, MCM2, and PARP1 after detergent solubility.
The protein expression level of each target protein was normalized to Lamin. The data
represent an average of 3 independent biological replicates. ImageJ quantification of
protein expression level is represented in Supplementary Figures 3A and 3B.
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Figure 2.4: Destabilizing oligomerization of R273H mtp53 does not block the
interaction between mtp53 and MCM2. HCT116 p53-/- cells were transfected with
wtp53, mtp53 R273H, or dual mutants R273H-R337C, R273H-A347D, R273H-L344P
expressing plasmids. (A) Analysis of p53/MCM2 complexes by in situ proximity ligation
assay (PLA). Fluorescent foci per cell were counted using Cellprofiler software and
depicted as a scatter plot using GraphPad Prism 9. The data represent a scatter plot with
n=3. An ordinary one-way ANOVA was used to determine the statistical significance of
the data. The following format was used to assign significance based on P-value: ****
represents a p-value ≤ 0.0001 and ns represent non-significant. (B) Representative
confocal microscope images of p53/MCM2 complexes (red) by in situ proximity ligation
assay (PLA), p53 expression (green) by immunofluorescence microscopy. DNA was
counterstained with DAPI (blue). The z-stack maximum intensity projection images are
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shown. Three independent experiments were performed. (Scale bar = 10µm). (C)
Analysis of p53/PARP1 complexes by in situ proximity ligation assay (PLA). Fluorescent
foci per cell were counted using Cellprofiler software and depicted as a scatter plot using
GraphPad Prism 9. The data represent a scatter plot with n=3. An ordinary one-way
ANOVA was used to determine the statistical significance of the data. The following
format was used to assign significance based on P-value: **** represents a p-value ≤
0.0001 and ns represent non-significant. (D) Representative confocal microscope images
of p53/PARP1 foci/complexes (red) by in situ proximity ligation assay (PLA), p53
expression (green) by immunofluorescence microscopy. DNA was counterstained with
DAPI (blue). The z-stack maximum intensity projection images are shown. Three
independent experiments were performed. (Scale bar = 10µm).
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Figure 2.5: Endogenous deletions in the OD of R273H mtp53 decreases the
interaction between mtp53 and MCM2. (A) Analysis of p53/MCM2 complexes by in situ
proximity ligation assay (PLA) in MDA-MB-468, R273HΔ381-388 and R273HΔ347-393
cells. Fluorescent foci per cell were counted by Cellprofiler software and depicted by a
scatter plot using GraphPad Prism 9. The data represent a scatter plot with n=3. An
ordinary one-way ANOVA was used to determine the statistical significance of the data.
The following format was used to assign significance based on P-value: **** represents
a p-value ≤ 0.0001 and ns represent non-significant. (B) Representative confocal
microscope images of p53/MCM2 foci/complexes (red) by in situ proximity ligation assay
(PLA) in MDA-MB-468, R273HΔ381-388 and R273HΔ347-393 cells. DNA was
counterstained with DAPI (blue). The z-stack maximum intensity projection images are
shown. Three independent experiments were performed. (Scale bar = 10µm).
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2.11 Supplementary Figures

Figure S2.1: GOF hotspot mtp53 predominantly forms tetramers. Cells were
harvested at 70-90% confluency by scraping and washing with cold PBS followed by
lysing. 50 μg of the resulting cell lysates were treated with either 0% (lanes 1,3,5,7,9) or
0.005% (lanes 2,4,6,8,10) glutaraldehyde for 20 min at room temperature. Samples were
run on an 8% SDS-PAGE and oligomerization determined by western blotting using antip53 DO1 antibody. Actin was used as a normalizer and showed very minor shift in mobility
with 0.005% glutaraldehyde. Data presented was reproduced in 3 biological replicates.
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Figure S2.2: Transactivation of CDC7 and RRM2 is not upregulated by mtp53.
HCT116 p53-/- cells transfected with plasmids expressing wtp53, or single mutants
R337C, A347D or L344P; or mtp53 R273H, or dual mutants R273H-R337C, R273HA347D, or R273H-L344P. Cells were harvested 24 hr post-transfection. The pellets were
divided into two and used for either protein or RNA extraction. RNA was extracted from
pellet and 5 μg of RNA used for cDNA synthesis. The mRNA message of CDC7 (A), and
RRM2 (B) measured by qRT-PCR. The data represent an average of 3 independent
biological replicates. A one-way ANOVA was used to determine the statistical significance
of the data. However, no statistically significant upregulation was observed. Wtp53, or
single mutants R337C, A347D or L344P (C) and mtp53 R273H, or dual mutants R273HR337C, R273H-A347D, or R273H-L344P (D) were lysed in RIPA buffer and 25 μg of
lysate loaded on a 10% SDS-PAGE and probed with anti-p53 DO1, anti-CDC7 and antiRRM2 antibodies. Actin was used as a normalizer. Data represent 3 independent
biological replicates.
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Figure S2.3: Destabilizing oligomerization of wtp53 does not block the interaction
with chromatin. The protein expression levels of mtp53, MCM2 and PARP1, normalized
to lamin were quantified using ImageJ. A graphical representation of the protein
expression for (A) chromatin fractionation and (B) detergent solubility assays are shown.
The date represents three independent biological replicates. The chromatin fractionation
assay was used to fractionate lysates prepared from HCT116 p53-/- cells transfected with
wtp53, or single mutants R337C, A347D, or L344P into cytosolic/soluble fraction and
chromatin/insoluble fraction. Binding of mtp53 and MCM2, to chromatin isolated from
partially purified lysed nuclei was assessed by western blot analysis. 25 μg of chromatin
protein was loaded on 10% SDS-PAGE gel. (C) A western blot depicting the chromatin
association of p53 and MCM2 after chromatin fractionation is depicted. The data
representative image of 2 independent biological replicates.
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Figure S2.4: Destabilizing oligomerization of wtp53 does not block the interaction
between mtp53 and MCM2. HCT116 p53-/- cells were transfected with wtp53, or single
mutants R337C, A347D, or L344P expressing plasmids. (A) Analysis of p53/MCM2
complexes by in situ proximity ligation assay (PLA). Fluorescent foci per cell were counted
using Cellprofiler software and depicted as a scatter plot using GraphPad Prism 9. The
data represent a scatter plot with n=3. An ordinary one-way ANOVA was used to
determine the statistical significance of the data. The following format was used to assign
significance based on P-value: **** represents a p-value ≤ 0.0001 and ns represent nonsignificant. (B) Confocal microscope images of p53/MCM2 complexes (red) by in situ
proximity ligation assay (PLA), p53 expression (green) by immunofluorescence
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microscopy. DNA was counterstained with DAPI (blue). The z-stack maximum intensity
projection images are shown. Three independent experiments were performed. (Scale
bar = 10 µm). (C) Analysis of p53/PARP1 complexes by in situ proximity ligation assay
(PLA). Fluorescent foci per cell were counted using Cellprofiler software and depicted as
a scatter plot using GraphPad Prism 9. The data represent a scatter plot with n=3. An
ordinary one-way ANOVA was used to determine the statistical significance of the data.
The following format was used to assign significance based on P-value: **** represents
a p-value ≤ 0.0001 and ns represent non-significant. (D) Confocal microscope images of
p53/PARP1 complexes (red) by in situ proximity ligation assay (PLA), p53 expression
(green) by immunofluorescence microscopy. DNA was counterstained with DAPI (blue).
The z-stack maximum intensity projection images are shown. Three independent
experiments were performed. (Scale bar = 10µm).
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The C-terminus of gain-of-function mtp53 R273H is required for association with PARP1
and Poly-ADP-Ribose
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3.1 Abstract
The p53 gene is mutated in 80% of triple-negative breast cancers. The mutant p53
(mtp53) R273H protein results from a gain-of-function (GOF) hot-spot gene mutation. This
GOF mtp53 protein assists in increasing cell proliferation and metastasis. Although GOF
mtp53 R273H has lost p53 site-specific DNA binding activity and tumor suppressor
transcriptional activity, the mtp53 protein is found in high levels in nuclei tethered to
chromatin. Mtp53 R273H associates with replicating DNA and Poly-ADP-Ribose
Polymerase 1 (PARP1), but how this interaction is regulated, and how it regulates cell
proliferation, is not well understood. Wild-type p53 interacts with PARP1 using a portion
of the C-terminus. In order to address whether the C-terminal region of mtp53 R273H is
important for chromatin interaction and breast cancer cell proliferation, we used CRISPRCas9 constructed MDA-MB-468 mutant cells with mtp53 R273H and C-terminal deletions
(R273HΔ381-388 and R273HΔ347-393). The mtp53 R273HΔ347-393 lacks the Cterminal regulatory domain and a portion of the oligomerization domain, and showed a
dramatic reduction in association with DNA, PARP1, and Poly-ADP-Ribose (PAR)
compared to mtp53 R273H full length and R273HΔ381-388. The cells expressing mtp53
R273HΔ347-393, had increased replication processivity and impaired response to
hydroxyurea (HU) replicative stress as exemplified by a lack of increased HU-induced
fork asymmetry. These changes in replication dynamics occurred in the presence of less
mtp53 R273HΔ347-393 on replicating DNA. Taken together our data suggest that the Cterminal region of GOF mtp53 R273H assists cells in DNA replication by facilitating
mtp53-PARP1 and PAR interactions.
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3.2 Introduction:
3.2.1 Wild-type p53 can regulate DNA replication
Wild-type p53 (wtp53) is well known for activating the transcription of target genes
that control cell cycle checkpoints 71. The TP53 gene is mutated in a majority of cancers
and no longer performs transcription factor functions which serve to maintain genomic
stability

71

. In fact, the TP53 gene is mutated in 80% of triple negative breast cancers

(TNBC), the most aggressive subtype of breast cancer

72

of wtp53 is participation in regulation of DNA replication

. A lesser-known guardian role
3,8,73

. The replication mediated

contributions of p53 help safeguard genomic integrity through inhibiting DNA replication
and improving DNA repair. The earliest studies on p53 replication-associated functions
were elucidated through interactions of wtp53 with the DNA tumor virus SV40

74,75

. Two

different interactions occur which include the wtp53 protein binding to SV40 DNA, and the
SV40 viral replication protein SV40 T antigen binding to, and inhibiting, p53 transcription
factor function

17,20,21,76

. SV40 T-antigen protein blocks wtp53 site-specific DNA binding

ability 21. Reciprocally, the wtp53 protein inhibits SV40 virus DNA replication. Importantly,
the functions of wtp53 for regulating DNA replication are not restricted to viral genomes
73

. Wild-type p53 associates with cellular replicating DNA

73,77

. When associated with

cellular genomes, wtp53 promotes DNA repair and influences the processivity of
replication forks (independent of activating the transcription of p21 and inducing the G1/S
checkpoint)

69,78-80

. The mechanism by which wtp53-replication protein interactions

influence DNA synthesis are not completely understood. Studies report both wtp53
dependent increases and decreases in replication fork processivity, depending on
variable study conditions. The mechanism of direct regulation of DNA synthesis by wtp53
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does not require the N-terminal transactivation domain, however roles for the other 3
functional domains have yet to be rigorously examined 77,81. GOF mtp53 (found in tumors)
and wtp53 share the same protein domains which include the N-terminal transactivation
domain, the central site-specific DNA binding domain (which is mutated by one amino
acid substitution in GOF mtp53), the adjacent oligomerization domain, and lastly a highly
charged C-terminal domain (CTD) 8. The missense mtp53 proteins are highly stable and
bind non-specifically to DNA and tightly tether to chromatin 8.

3.2.2 The C-terminus of wild-type p53 non-covalently interacts with PARylated
PARP1
The proposed mechanism by which the C-terminus of wtp53 interacts with DNA is
through a sliding clamp model

82

. In the sliding clamp model, the CTD mediates fast

sliding, while the central site-specific DNA binding domain associates with DNA and must
hop from region to region. The C-terminus of wtp53 is also involved in other important
interactions, one of which is association with Poly-ADP-Ribose Polymerase 1 (PARP1)
83,84

. The major substrate of PARP1 is PARP1 itself, and the p53 C-terminus interacts

non-covalently with the Poly-ADP-Ribosylated (PARylated) PARP1 protein

34

. Upon

interacting with PARP1, wtp53 is then modified by the enzymatic activity of PARP1, and
wtp53 becomes PARylated

34

. When PARP1 associates with DNA damage, it

conformation changes and it begins to move on chromatin while sequentially PARylating
itself, and histones, as it moves using a “monkey bar” model 85. This chromatin interaction
coupled with the enzymatic activity of PARP1 helps to safeguard the repair of lagging
strand DNA replication

86,87

. However, how the C-terminus of wtp53 and/or mtp53 might
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participate in the function of PARP1 on replicating DNA is not yet understood. What is
known is that GOF mtp53 R273H associates with PARP1 and replicating DNA 38.

3.2.3 Mutant p53 R273H interacts with replicating DNA and PARP1
Our laboratory determined that GOF mtp53 R273H interacts with PARP1 and
replicating DNA using several different methodologies including proteomics, molecular
biology, and mouse model studies 8,35,38,53,88. In a subcellular proteomics screen of TNBC
cells, using genetically engineered mtp53 knockdown cell line MDA-MB-468 (with or
without mtp53 R273H expression), we determined the gain-of-function proteome changes
that correlated with having high levels of mtp53 R273H

53

. Loss of mtp53 R273H

associates with the chromatin reduction of several replication-associated proteins,
including PARP1 and all six members of the replication helicase Mini Chromosome
Maintenance (MCM) complex 35. Moreover, the interaction between mtp53 and replication
machinery is recapitulated in tumors in genetically modified mice that express a GOF
mtp53 analogous to mtp53 R273H

35

. The human p53 R273H (in a number of different

cell lines) was then shown to be in close proximity to both PARP1 and MCM proteins 38.
Furthermore, studies showed that mtp53 R273H interacts with newly synthesized DNA
and having mtp53 expression associates with higher levels of PARylated proteins in
cancer tissue

38

. This information pointed to a potentially important connection between

mtp53, PARP1, and PARP enzymatic activity in tumor cell survival. A strong positive
correlation between high expression of mtp53 and PARP1 exists in the Cancer Genome
Atlas (TCGA) data set for breast cancers, and also in a small cohort of ethnically diverse
breast cancer samples 38.
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3.2.4 GOF mtp53 sensitizes breast cancer cells to PARP1 inhibitors
The association of high PARP activity and blocking the PARP1 activity with
pharmacological PARP inhibitors is now a standard of care for breast cancers with
BRCA1 mutations

89-91

. Both loss of p53 function and GOF mtp53 expression sensitize

cancer cells to PARP inhibition. Colon cancer HCT116 cells in a xenograft mouse model
lacking wtp53 tumor suppressor function are more sensitive than their corresponding
isogenic wtp53 counterpart to the PARP inhibitor Olaparib linked to a radio-ligand for
delivery of targeted DNA damage

92

. In addition, the expression of mtp53 increases the

sensitivity of breast cancer cells to combination temozolomide and talazoparib treatment
35,38

. This increased sensitivity associates with reduced cell cycle arrest, increased

PARP1 trapping on chromatin, increased DNA damage and cell death 35,38,92.

3.2.4 Loss of the mtp53 C-terminus induces replication stress and reduces
interaction with MCM proteins independent of oligomerization.
The tetramerization of wtp53 is required for full tumor suppressor transcription
function, but is not needed for mtp53 to associate with chromatin 93. We recently observed
that MDA-MB-468 cell lines with mtp53 R273HΔ381-388 and mtp53 R273HΔ347-393
both exhibit replication stress phenotypes

61

. Additionally, we detected that mtp53

R273HΔ347-393 no longer interacts well with chromatin or in close proximity to MCM
proteins 61,93. A small deletion of just a portion of the C-terminus, mtp53 R273HΔ381-388,
moderately disrupts mtp53 R273H replication function while a complete deletion of the Cterminal region, mtp53 R273HΔ347-393 causes more profound changes

61,93

. As such,

herein we examined if the C-terminal end of mtp53 R273H was required for the mtp53 to
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interact with PARP1, PAR, and replicating DNA. We found that complete deletion of the
C-terminal region, mtp53 R273HΔ347-393, disrupted the interaction with PARP1, PAR,
and reduced replication asymmetry in response to HU-induced replication stress.
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3.3 MATERIALS AND METHODS
3.3.1 Materials
Solvents and chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA). DO1
p53 (Cat# sc-126) monoclonal mouse and PARP1 (Cat# sc-7150) rabbit polyclonal
antibodies were purchased from Santa Cruz (USA). Rabbit polyclonal antibodies
against p53 (Cat# 10442-1-AP) and PARP1 (Cat# 13371-1-AP) were purchased from
Proteintech. Additional antibodies against PARP1 were purchased from BD Biosciences
(mouse monoclonal; Cat# 51-6639GR) and Cell Signaling Technology (rabbit
polyclonal; Cat# 9532s). Anti-PCNA mouse monoclonal Cat# NBP2-80905 was
purchased from Novus Biologicals. An Eppendorf 5415 refrigerated centrifuge was used
for preparation of all extracts.

3.3.2 Cell culture
Human breast cancer cell line MDA-MB-468 (RRID:CVCL_0419) was purchased from
ATCC (www.atcc.org) and the HCT116 (RRID:CVCL_S744) colon cancer cell line that is
p53-/- was a gift from Bert Vogelstein 59,60. Cells were routinely checked for mycoplasma
contamination by PCR assay (ATCC) and maintained at 5% CO2 in a 37°C humidified
incubator in culture for ≤ 30 passages. HCT116 p53-/- and MDA-MB-468 cells were
cultured in McCoy’s 5A (Gibco) and DMEM media (Corning) respectively, with 50 U/ml
penicillin, 50 μg/ml streptomycin (Mediatech), 5 µg/ml plasmocin (InvivoGen) and
supplemented with 10% FBS (Gemini).
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3.3.3 Whole cell lysis and immunoblotting
Cells were harvested at 1,400 g (1100 rpm) for 5 min at 4°C on Sorvall benchtop
centrifuge. Cells were washed three times with ice-cold PBS and resuspended in RIPA
buffer (0.1% SDS, 1% IGEPAL NP-40, 0.5% Deoxycholate, 150 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 50 mM Tris-Cl pH 8.0, 1 mM PMSF, 8.5 µg/ml Aprotinin, 100 µM
phosphatase inhibitor cocktail (Sigma), and 2 µg/ml Leupeptin). The cell suspension was
incubated on ice for 30 min to lyse the cells, vortexing every 5 min. Additional sonication
of lysate for 3x for 30 sec pulses/ 30 sec rest on ice at 98% amplitude was done after the
incubation. Samples were centrifuged at 15,700 g (13,200 rpm) for 30 min at 4°C, the
supernatant collected, and protein quantified via Bradford Assay (Bio-Rad). Cell extracts
were run on SDS-PAGE to separate samples followed by electro-blotting onto
polyvinylidene fluoride (PVDF) membrane (GE-Healthcare Amersham Biosciences). The
membrane was blocked with 5% non-fat milk (Bio-Rad) in 1X PBS-0.1% Tween-20
followed by incubation with primary antibody overnight at 4°C. The membrane was
washed 3x with either 1X PBS-0.1% Tween-20 and incubated with Cy5 and Cy3linked secondary antibodies for 1 hr at room temperature. The signal was detected with
the Typhoon FLA 7000 laser scanner (GE Healthcare). Quantification of western blot
signal was done by densitometry using ImageJ.

61

3.3.4 DNA Fiber Assay
Cells were treated with Iododeoxyuridine (IdU) (50 µM) for 10 min followed by washes in
warm PBS 2x, then treated with Chlorodeoxyuridine (CldU) (50 µM) for 30 min. This was
followed by washes in PBS 2x and then removal of cells from the plate by trypsinization.
Centrifugation was carried out at 1,500 g (1200 rpm) for 5 min at 4°C to remove trypsin
and cells were resuspended in PBS at a density of approximately 1x106 cells/mL. Cells
were then spotted onto a clean microscope slide in a volume of 2 µL and lysed with 7µL
lysis buffer (0.5% SDS in 200 mM Tris-HCl pH 7.4, 50 mM EDTA) by pipetting the mixture
on the slide several times and then incubating for 6 min at room temperature. Following
lysis, slides were tilted at an angle of roughly 30° and the lysis solution was allowed to
run down the slide, which were air dried and then fixed in a solution of 75% methanol/25%
glacial acetic acid for 4 min at room temperature in a Coplin jar. Post-fixation, slides were
air dried and stored overnight at 4°C. For staining, slides were first treated with 2.5 N HCl
for 30 min at room temperature in a Coplin jar, washed 3x with PBS, and then placed in
blocking solution (10 % goat serum/ 0.1 % Triton X-100 in PBS) for 1 hr at room
temperature. Next, slides were incubated for 1 hr at room temperature with primary
antibodies against IdU and CldU (each at 1:100 dilution in blocking buffer) and kept in the
dark. Following 3 washes with PBS, slides were incubated with secondary antibodies
(each at 1:350 dilution in blocking buffer) for 1 hr at room temperature, washed again 3x
with PBS, air dried in the dark, and then finally mounted using 70 µL Prolong Gold
mounting media (Invitrogen) with a coverslip. Slides were dried overnight and visualized
on a Nikon A1 confocal microscope with a 60X objective lens. All subsequent analyses
were done on NIS Elements, ImageJ, and GraphPad Prism 9.
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3.3.5 Flow Cytometry
Sub-confluent cells were synchronized with aphidicolin (block cell cycle at early S phase)
(5 µM) for 24 hours and released into fresh media. Cells were harvested at selected time
points by trypsinization and spinning in a tabletop bucket centrifuge (at 4°C) at 2000 g
(1500 rpm) for 5min. Cells were washed and resuspended in ice cold PBS at a density of
2x106 cells/mL. Cells were fixed by adding cell suspension dropwise into a solution of
70% ethanol while vortexing continuously. Cells were stored at -20°C overnight and then
spun down and resuspended in 500 µL propidium iodide staining solution (0.1% Triton X100, 200 µg/mL RNAse A, 60 µM propidium iodide in PBS), filtered through a nylon mesh
(to separate clumped cells) into a polystyrene tube, and analyzed on a flow cytometer.
Analysis was done with FlowJo 10.7 (FlowJo, RRID:SCR_008520) and GraphPad Prism.

3.3.6 Proximity Ligation Assay (PLA)
The protocol for the proximity ligation assay using the Sigma Aldrich Duolink KitTM (Cat #
DUO92008) was performed as described previously 38. Briefly, cells were seeded in a 12well glass-bottomed plate at 1x105 cells per well in complete DMEM media supplemented
with 10% FBS and 50 U/ml penicillin, 50 μg/ml streptomycin (Mediatech). Sub-confluent
cells were washed 3x with ice cold PBS for 2 min/wash. The cells were then fixed in 4%
formaldehyde for 15 min and permeabilized in PBS containing 0.5% Triton X-100 for 10
min at room temperature. The Duolink In-situ Red Kit (Cat # DUO92101) was used for
the PLA. Blocking buffer was added to each well and incubated in a humidified chamber
at 37oC for 30 min. After aspirating the blocking buffer, primary antibodies were added to
each well and incubated in a humidified chamber overnight at room temperature. Wash
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buffer A (cat # DUO82049) was used to wash the cells 3x for 5 min/wash. The PLA
Plus/Minus secondary antibody probes were added to the wells and incubated in a
humidified chamber for 60 min at 37oC. After that, the cells were washed 2x with buffer A
for 2 min/wash. The subsequent ligation and amplification steps (with washing 2x
2min/wash with buffer A in between) were performed as specified by the manufacturer
(ligation 30 min at 37oC; amplification 100 min at 37oC). After the amplification step, cells
were washed 3x and mounted without coverslips as specified by the manufacturer.
Images were taken using the Nikon A1 confocal microscope and processed with the
Nikon NIS Element software, ImageJ and Cellprofiler. The number of foci/cells were
determined, and data analysis was performed in GraphPad Prism 9.
3.3.7 Immunoprecipitation (IP) from extracts prepared using NP40 buffer
Cells were lysed in NP40 buffer (50mM Tris pH 8.0, 5mM EDTA, 150mM NaCl, 1mM
DTT, 0.5% NP-40) and passed through a 211/2 gauge needle 10x every 10 min at 4°C for
a total of 30 min. Lysates were centrifuged at 15,700 g (13,200 rpm) for 15 min at 4°C
and supernatant transferred to a new tube. After protein quantification by the Bradford
assay, 1 mg total protein was pre-cleared by adding 1 µg mouse IgG and 30 µL of protein
A/G plus agarose beads and rotating at 4°C for 30 min. Beads were spun down at 1500
g (4000 rpm) for 1 min at 4°C and the supernatant transferred to a new tube to which
antibody-conjugated agarose beads were added. Assembled IP reactions were rotated
at 4°C overnight. The following day, beads were spun down at 1500 g (4000 rpm) for 1
min and washed 4x with 1 ml wash buffer (50 mM Tris pH 8.0, 5 mM EDTA, 150 mM
NaCl). After the last spin, 2x SDS Laemmli sample buffer with 50 mM DTT was added on
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top of the beads, which were then heated at 70°C for 10 mins, and spun down at 13,200
rpm for 1 min. The supernatant was analyzed by SDS-PAGE.

3.3.8 Immunoprecipitation (IP) from extracts prepared using CHAPS buffer
Cell were lysed in three volumes of CHAPS buffer (50 mM KxPO4 pH 7.4, 1 mM
DTT, 1 mM EDTA, 100 mM NaV, 50 µM NaF, 250 mM NaCl, 7 mM CHAPS, 10% Glycerol,
10 mM β-glycerol phosphate, 0.5 mM PMSF, 5.0 µg/mL Leupeptin) for 30 min on ice, with
intermittent mixing by gently vortexing. Cell lysates were clarified by centrifugation at
13,000 rpm for 20 min at 4ºC, and then 1 mg total protein (~100 µL) was pre-cleared with
1 µg mouse IgG and 30 µL of protein A/G plus agarose beads (Santa Cruz Biotechnology)
equilibrated with binding buffer (50 mM Tris pH 8.0, 5mM EDTA, 150 mM NaCl, 1mM
PMSF, 8.5 µg/mL aprotinin, 100 µM phosphatase inhibitor cocktail (Sigma), and 2 µg/mL
leupeptin) in a volume of 1ml (final IP buffer conditions were 0.1x Chaps buffer/0.9x
binding buffer) and rotated for 30 min at 4ºC. Pre-cleared extracts were collected after
removal of the IgG beads by centrifugation at 1500 g (4000 rpm) and divided into two
aliquots for IP with either 30 µL of anti-p53 DO1-AC antibody beads (Santa Cruz) or
normal mouse agarose conjugated normal immunoglobulin (IgG-AC) beads. IP reactions
were incubated by rotation at 4ºC overnight, and IP beads collected as described above
were washed at 4ºC 4x with 1 mL binding buffer. Bound proteins were eluted by
incubating in 2x SDS Laemmli sample buffer containing 200 mM DTT at 90ºC for 10 min.
Eluates were collected and analyzed by SDS-PAGE and western blotting.
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3.3.9 Site-directed mutagenesis, clone validation and transfection
The NEBasechanger platform was used to design primers to introduce point mutations
within the DNA binding domain of pLNCX (RRID: Addgene_17245) plasmids expressing
wtp53 6KR (to maintain charge) or wtp53 6KQ (to mimic acetylation), generously gifted
from

the

Carol

Prives

lab.

For

R273H,

the

primer

sequences

are

Forward: TTTGAGGTGCaTGTTTGTGCC
and Reverse: GCTGTTCCGTCCCAGTAG. Mutagenic PCR was carried out with the Q5
mutagenesis kit (NEB) at the primer-specific recommended annealing temperature of
64°C. After confirming PCR amplification by agarose gel electrophoresis, a KinaseLigase-Dpn1 (to phosphorylate and ligate amplicon as well as digest template DNA
respectively) (NEB) reaction was done prior to transforming DH5a competent cells.
Clones were inoculated in LB+ampicillin (50µg/mL) media and plasmids were purified
with the Qiagen miniprep/midiprep kit and sent for sequencing (Genewiz) using a
p53 Exon 8 forward primer (5’ ACAGCACATGACGGAGGTTGT). Sequences were
compared to TP53 cDNA using the Benchling platform. Plasmids were transfected into
HCT116 p53-/- cells using lipofectamine 2000 (Thermofisher). For lipofectamine, cells
were seeded at 50-60% confluency in McCoy’s 5A media + 10% FBS without
antibiotics 24hr before transfection. The amount of plasmid DNA and lipofectamine were
optimized based on the protocol from Thermofisher. On the day of transfection, plasmid
DNA and lipofectamine were diluted in Opti-MEM (Thermofisher) and incubated for 20
min at room temperature after mixing. The DNA-lipofectamine complex was added to cells
and incubated for 4 hr before changing media to McCoy’s 5A media + 10% FBS with
antibiotics and harvested 24 hr after transfection by scraping.
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3.3.10 Chromatin fractionation assay
Localization of mtp53 proteins to chromosomes was assessed using a version of the
Chromatin Fractionation Assay as described

61

. Sub-confluent cells were harvested as

dictated by experimental conditions by scraping, pelleted, and washed 3x with ice-cold
PBS. The pellet was resuspended in Buffer A (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2,
300 mM Sucrose, 1mM DTT, 10% Glycerol, 0.1 mM PMSF, 1 μg/ml Leupeptin, 1 μg/ml
Pepstatin A, and 2 μg/ml Aprotinin) with 0.1% Triton X-100 using 3X the pellet volume.
The resuspended pellet was centrifuged at 1,500 g (4,000 rpm) for 5 min after incubating
on ice for 5 min. The resulting pellet containing nuclei was saved and the supernatant
spun at 15,700 g (13,200 rpm) for 5 min; the supernatant from this centrifugation step
was saved as S1. The nuclei from each sample were washed twice in Buffer A + 0.15%
Triton X-100 then lysed in Buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 0.1 mM
PMSF, 1 μg/ml Leupeptin, 1 μg/ml Pepstatin A, and 2 μg/ml Aprotinin) on ice for 30 min.
The chromatin for each sample was separated from the nuclear lysate (S2) by
centrifugation for 4 min at 1,500 g (4,000 rpm) at 4°C, washed with Buffer B, and then
collected by centrifugation as described above. The chromatin pellet was resuspended in
Buffer B and sonicated on ice to shear genomic DNA; the resulting solution was saved
as the chromatin fraction. The protein concentrations were measured using the Bradford
assay (Bio-Rad). Actin and Lamin were used as loading controls.

67

3.3.11 Isolation of Protein on Nascent DNA (iPOND)
The iPOND assay was performed as previously described

38

with little modification. Ten

15 cm plate of cells for each cell line was cultured until each plate was 70-80% confluent
a day before 5-ethynyl-2 -deoxy uridine (EdU) incubation. Cells were incubated with EdU
diluted in complete DMEM media to a concentration of 10 µM EdU for 45 min. Media was
discarded and cells were fixed with 10 mL 0.5% formaldehyde in PBS for 20 min and
quenched by adding 1 mL 1.25 M glycine. Permeabilization of cells was done in 0.25%
Triton X-100 in PBS for 30 min and subsequently underwent a click reaction (to conjugate
the biotin to EdU labelled DNA). Click reaction was 2 mM Copper Sulfate,10 mM Biotinazide, and 10 mM Sodium Ascorbate added to PBS for 2.0 hr at room temperature with
rotation. Cells were incubated in RIPA buffer 930mM HEPES, pH 7.4,150mM NaCl, 1%
Nonidet P-40,0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 5mM EDTA,
1mM NaV04, 50mM NaF, 1mM PMSF, 10% Pepstatin A, 10 μg/ml leupeptin, and 10 μg/ml
aprotinin) on ice for 30 min, vortexing every 5 min. Additional sonication of lysate (18 on
ice for 30 sec on/off at 98% amplitude) was done after the incubation. Samples were
centrifuged at 15,700 g (13,200 rpm) for 30 min at 4ºC. Biotin-EdU–labeled DNA was
incubated with Streptavidin–agarose beads at 4ºC for 20 hr. The beads were washed 3x
with RIPA buffer and proteins bound to nascent DNA were eluted by incubating in 2x SDS
Laemmli sample buffer containing 0.2 M Dithiothreitol (DTT) for 25 min at 95ºC. Samples
were run on an SDS-PAGE gel and western blot analysis used to determine the levels of
protein expression in each lane.
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3.3.12 Data quantification and Statistical Analysis
Western blot data were quantified using ImageJ (ImageJ, RRID:SCR_003070). Statistical
analyses

were

conducted

in

Excel

or GraphPad Prism

9

(GraphPad

Prism,

RRID:SCR_002798). Results are expressed as mean + SEM. Statistical significance for
hypothesis testing was performed by two-tailed Student's t-test of unknown variance and
analysis of variance multiple comparisons.
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3.4 Results:
3.4.1 CRISPR-Cas9 Mutagenesis and Site Directed Mutagenesis
We compared alternate C-terminal versions of mtp53 R273H and refer to these
variants as dual mutants (Figure 3.1A). The human triple negative breast cancer cell line
MDA-MB-468 expresses only mtp53 R273H and has no wtp53 due to loss of
heterozygosity. This was compared to three CRISPR-Cas9 C-terminal endogenous
deletion variants. The variants included two truncated proteins, mtp53 R273HΔ381-388,
and mtp53 R273HΔ347-393, as well as a frameshift mtp53 R273Hfs387, which we
previous reported reduces protein expression (Figure 3.1B). The C-terminus of wtp53,
and its post-translational modification, regulate the transcription factor functions of the
protein

30,33,94,95

. Mouse model studies show that deletion of the C-terminus results in

wtp53 activation 33,95. Comparing the functional properties of the wtp53 C-terminus in vitro
and in a mouse-model indicates that deletion of the C-terminus alters the spectrum of
site-specific DNA binding interactions with p53 responsive elements (in some cases
increasing transcriptional activation of target genes). However, in the case of mtp53 there
is no interaction with p53 responsive elements so the C-terminus would regulate proteinprotein interactions and non-specific chromatin interactions. In order to address how the
C-terminus of mtp53 influenced protein-protein interactions, and the ability to interact nonspecifically with chromatin we transiently transfected HCT116 p53-/- cells with plasmids
expressing mtp53 R273H, mtp53 R273H 6KQ (to mimic acetylation), mtp53 R273H 6KR
(to maintain charge) and mtp53 R273HΔ24 removing a small C-terminal portion. When
transiently transfected into HCT116 p53-/- cells, we observed similar expression of the
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mtp53 proteins (see Figure 3.1C). We then embarked on a comparison of biochemical
properties of endogenously and exogenously expressed mtp53 R273H proteins.

3.4.2 C-terminal deletion of mtp53 R273H disrupts the interaction with PARP1 and
PAR.
We previously reported that MDA-MB-468 CRISPR-Cas9 p53 C-terminal deletion
clones, expressing mtp53 R273HΔ381-388 or mtp53 R273HΔ347-393, exhibit increased
replication stress

61

. As such, we hypothesized that the transcription-independent DNA

replication function of p53 is executed by a CTD-dependent p53-PARP complex that is
retained in the mtp53-PARP axis. To determine if deletion of portions of the C-terminus
interrupted the ability of endogenously expressed mtp53 R273H to interact with PARP1,
we utilized the proximity ligation assay (PLA), which we previously used to report on the
mtp53-PARP1 interaction

38

. The PLA results demonstrated, as expected, that in MDA-

MB-468 mtp53 R273H and PARP1 are in close proximity (Figure 3.2A, purple dots
indicate foci counts). Both the small C-terminal deletion (R273HΔ381-388), and the large
deletion (R273HΔ347-393), resulted in statistically significant reductions in the
mtp53/PARP1 interaction (Figure 3.2A, R273HΔ381-388 shown by red dots, and
R273HΔ347-393 shown by green dots with representative confocal microscope images).
In addition, we investigated whether mtp53 interacting with total PARylated proteins
showed a reduced interaction when the C-terminus of mtp53 R273H was deleted. We
observed a decrease in the proximity of both R273HΔ381-388 and R273HΔ347-393 Cterminally deleted mtp53 R273H with PARylated factors (Figure 3.2B). This was not
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surprising as it has been reported that the C-terminus of wtp53 interacts with the
PARylated portion of the protein PARP1.
We used co-immunoprecipitation experiments to assess whether the interaction of
C-terminal deletion mutants R273HΔ381-388 and R273HΔ347-393 resulted in less coimmunoprecipitation of PARP1. Like wtp53, mtp53 R273H co-immunoprecipitates
PARP1 protein

38

(Figure 3.2C, lane 3). However, the co-immunoprecipitation

experiments demonstrated that C-terminal deletion mutants R273HΔ381-388, and
R273HΔ347-393, resulted in decreased interaction with PARP1 (Figure 3.2C, lanes 6 and
9). The large deletion R273HΔ347-393, missing the entire CTD and a small portion of the
oligomerization domain, showed a more striking reduction in the ability to coimmunoprecipitate PARP1 (Figure 3.2C, lane 9). We previously showed that disruption
of mtp53 R273H oligomerization (while maintaining the CTD) does not disrupt the
interactions of mtp53 R273H with chromatin or replication machinery

93

. As such, we

concluded that the reduction seen was due to the CTD deletion.

3.4.3 Changing mtp53 R273H Six C-terminal lysines to either arginine or glutamine
maintains the interaction of mtp53 with chromatin and increases the interaction
with PARP1.
In order to further address ways in which the CTD of mtp53 R273H influences DNA
and PARP1 interactions, we exogenously expressed proteins in HCT116 -/- cells (see
Figure 3.1). Expression of mtp53 R273H, mtp53 R273H 6KQ (to mimic acetylation),
mtp53 R273H 6KR (to maintain charge), and mtp53 R273HΔ24 removing a small Cterminal portion, and the negative control of plasmid expressing EGFP were compared
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for their ability to produce protein that interacted with chromatin (Figure 3.3A). We
observed that small changes to the CTD of mtp53 resulted in proteins that had a similar
chromatin interaction ability (Figure 3.3A, lanes 6-10). The C-terminal lysines of wtp53
are important for regulation of p53 function and alter the spectrum of protein-protein
interactions, and downstream functions, in ways that continue to be discovered

96

.

Acetylation of DNA repair proteins, and histones, play multiple differential regulatory roles
for protein ADP-ribosylation

97,98

. As such, it was difficult to predict what changing the 6

C-terminal lysines would do to the interaction of mtp53 with PARP1 and PAR. Moreover,
the small Δ24 deletion of wtp53 can activate, or repress, gene expression by multiple
mechanisms depending on tissue context

33

. We compared the ability of transiently

transfected p53 proteins to co-immunoprecipitate PARP1, and total PARylated proteins
(Figure 3.3B). Immunoprecipitation of p53 was evident except for when the HCT116-/cells were transfected with the negative control GFP expressing plasmid (Figure 3.3B,
lane 18). There was an enrichment of p53 protein above that seen in 1% input samples
(Figure 3.3B, p53 lanes 3,6,9,12, and 15). Interestingly, we observed that mtp53 R273H
6KQ reproducibly co-immunoprecipitated a striking amount of PARP1, and that mtp53
R273HΔ24 reproducibly immunoprecipitated a lower form of PARP1 (which may be nonPARylated) (Figure 3.3B, PARP1 lanes 9 and 15). The mtp53 R273H 6KR protein coimmunoprecipitated PARP1 in levels that ranged from similar to, and higher than, mtp53
R273H

in

different

experiments

(Figure

3.3B,

PARP1

lane

12).

This

co-

immunoprecipitation showed major enrichment above the input such that we could only
see input for PARP1 with very long exposure times (see supplementary S1). We also
detected the co-immunoprecipitation of high mobility total PARylated proteins, some of
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which may be PARylated PARP1, as they strongly correlated with PARP1 results (Figure
3.3B, PAR lanes 3, 6, 9, 12, and 15). No co-immunoprecipitation of PARP1, or total
PARylated protein, was evident in eGFP negative control samples (Figure 3.3B, lane 18).
This indicated that mtp53 R273H interacts with PARylated PARP1 and that minor
changes to the CTD can shift the forms and amounts of PARP1-mtp53 interaction.

3.4.4 Loss of the mtp53 R273H C-terminal domain and part of the oligomerization
domain impair response to HU-induced replication stress.
The p53 protein allow cells to tolerate DNA damage in a variety of ways. One
mechanism is by regulating the speed of DNA replication processivity. Wild-type p53
slows replication speed while the site-specific DNA binding mutants R248W and R273H
do not

77

. Moreover, both mtp53 R273H and mtp53 R248W inhibit hydroxyurea (HU)-

mediated replication stress by promoting the interaction of TopBP1 with Treslin and thus
allowing DNA synthesis even in the presence of cyclin dependent protein kinase 2 (Cdk2)
inhibitor

39

. PARP is also involved in protecting replication forks and inhibition of PARP

protein increases replication processivity and cell death by mitotic catastrophe

99

. We

used DNA fiber analysis to test if the alteration of the C-terminus of mtp53 R273H in MDAMB-468 cells resulted in different fork speeds, and/or differential response to replication
stress induction by hydroxyurea (HU) treatment (Figure 3.4). All cell lines treated with HU
demonstrated statistically significant reduced replication speeds (compare Figures 3.4A3.4D, left panels). The origin firing of these cell lines did not show a statistically significant
change in the presence of HU (see supplementary Figure S3.2). Replication stress, as a
result of DNA aberrations, takes many forms including increasing replication fork
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asymmetry resulting from fork stalling and uncoupling; such asymmetry can be detected
by DNA fiber analysis100 (Figure 3.4 see right panel). When cells were treated with HU,
the cells expressing mtp53 R273HΔ347-393 did not experience a statistically significant
increase in fork asymmetry (Figure 3.4C), while full-length, mtp53 R273HΔ381-388, and
R273Hfs387 did (Figures 3.4A, B, and D). Interestingly, mtp53 R273HΔ347-393 cells
showed an increased replication speed compared to the MDA-MB-468 mtp53 R273H
(Figure 3.4C mean 0.300 kb/min compared to Figure 3.4A mean 0.279 kb/min).

3.4.5 C-terminal deletion of mtp53 R273H reduces p53 on replicating DNA and
decreases the ability of cells to proceed through the G2/M checkpoint.
The function of the mtp53 R273H C-terminus for influences of PARP1 on
replicating DNA has never been evaluated. We assessed if removal of the mtp53 R273H
C-terminus influenced the interaction of PARP with replicating DNA, or if such deletions
influenced the progression of MDA-MB-468 cells through the cell cycle. We used
immunoprecipitation of nascent DNA to evaluate the interaction of mtp53 proteins,
PARP1, and Proliferating Cell Nuclear Antigen (PCNA) on replicating DNA in the MDAMB-468 cells with either mtp53 R273H, mtp53 R273HΔ381-388, or mtp53 R273HΔ347393 (Figure 3.5A). The removal of the C-terminus in these cell lines reduced the
interactions seen by PLA, and co-immunoprecipitation, with both PARP1 and PAR (Figure
3.2). We observed that the overall interactions of PARP1 and PCNA with replicating DNA
were not reduced by removal of the mtp53 C-terminus (Figure 3.5A, see PARP1 and
PCNA). As expected, there was very low mtp53 R273HΔ347-393 on nascent DNA and
reduced mtp53 R273HΔ381-388 on nascent DNA (Figure 3.5A). Previously, we evaluated
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these cells for S-phase cell cycle progression by flow cytometry and observed small
delays in the progression of cells containing R273HΔ381-388 and R273HΔ347-393
mutations and a large delay in cells containing the R273Hfs387 mutation

61

. Here, we

evaluated the progression of the C-terminal deletion mutants via flow cytometry following
synchronization with aphidicolin for 24 hours. The increased processivity and low
asymmetry observed for mtp53 R273HΔ347-393 HU-treated cells, did not translate into
any difference observed for the release from an aphidicolin cell cycle block (even though
their general proliferation was reduced). We observed that cells harboring the
R273HΔ381-388 mutant following synchronization with aphidicolin started with more cells
in G2/M as compared to cells expressing either full length R273H or R273HΔ347-393
(Figure 3.5B and 3.5C). After a 20-hour release from aphidicolin we observed that cells
containing the R273HΔ381-388 mutant recovered and all the profiles looked similar.
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3.5 Discussion:
3.5.1 The C-terminal domain of mtp53, like wtp53, regulates the interaction with
PARP1
The CTD of p53 has been shown to have many functions that regulate its activity,
which include interactions with multiple proteins, and sites for post-translational
modifications

71

. Changes to the C-terminus of p53 in mouse models interfere with

development and result in lethality 33,94,95. The CTD of wtp53, which contains many sites
for post-translational modification, is a central hub for the non-covalent interaction with
PARylated PARP134. The multiple posttranslational modifications that can occur on
cancer expressed mtp53 proteins will represent different mtp53 proteoforms (which refers
to specific protein molecules resulting from post-translationally modified and cleaved
variants)

101

. The most common general proteoform change for all proteins is lysine

acetylation, and the six C-terminal lysines of mtp53 will allow for this modification in
different cellular contexts

101

. Studies in vitro showed that the CTD of both wtp53, and

synthetically designed multiple hot-spot mutation DNA binding mutated p53, interacts
strongly with PAR chains, and the p53 CTD non-covalent interaction with PAR chains is
preferred over non-specific DNA binding 102. As such, one interpretation of what different
GOF mtp53 forms do in cancer cells is their interaction with the PARylated proteins, with
variable mtp53 forms altering the spectrum of protein-protein interactions that occur.
Hotspot missense mutants of p53 in human breast cancers retain an intact CTD
and produce highly stable proteins. However, the function of the mtp53 CTD has not been
elucidated. We asked if mtp53 R273H, like wtp53, could interact with PARP1 and PolyADP-Ribosylated proteins. We found that the C-terminal amino acid residues of mtp53
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R273H played an important role for bringing endogenous mtp53 R273H in close nuclear
proximity to both PARP1 and total PARylated proteins (Figure 3.2). This result was seen
using in situ PLA microscopy and immunoprecipitation. As such, while DNA may be
assisting in the interaction, the interaction is not an artifact from extract preparation. The
co-immunoprecipitation of high mobility PARP with mtp53 R273H suggested that the
interaction was with the modified Poly-ADP-Ribosylated PARP. The six C-terminal lysine
residues of wtp53 can be PARylated by PARP, and these amino acids are the same
residues of the protein that can be post-translationally modified by other enzymes known
to regulate cell fates. We observed that changing the six C-terminal lysine residues to
glutamine (which mimics acetylation) increased the interaction of mtp53 R273H with
PARP, and that deleting the last 24 amino acid residues of mtp53 R273H increased an
interaction with a form of PARP that was faster migrating (which we think is less
PARylated PARP). The data shown herein allows for multiple interpretations and of what
a full-length CTD contributes to mtp53 function. One interpretation is that the mtp53
protein changes its partner protein selection dynamics when the last 24 amino acids of
CTD is missing or when residues within the CTD are post-translationally modified.
Another interpretation is that PARP modifies the CTD of mtp53 to set in motion a range
of different signaling pathways (some of which are usually in play for wtp53, but the sitespecific DNA binding ability is dominant). Further experiments are required using in situ
techniques like PLA to determine if modification of the CTD amino acids can block and/or
assist in the mtp53-PARP nuclear interactions.
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3.5.2 Potential reasons for connections between mtp53 and PARP and Poly-ADPRibose
The non-covalent interaction of mtp53 R273H with PARP1 and Poly-ADP-Ribose
through C-terminal amino acids may serve multiple regulatory functions in the absence
of wtp53 tumor suppressor activity. First, this interaction may serve to help stabilize mtp53
R273H in cells. Second, it may assist in the regulation of chromatin organization, as
PARylation of chromatin factors is known to regulate remodeling

103,104

. PARP1 can

enzymatically PARylate many proteins that have C-terminally disordered regions like p53
34,102

. An interpretation for why mtp53 R273H may have a strong connection to Poly-ADP-

Ribosylated PARP1 is, in part, because it has lost site-specific DNA binding activity. The
freedom from binding site-specifically to DNA releases mtp53 to more strongly interact
non-covalently with Poly-ADP-Ribose

102

. The MDA-MB-468 TNBC cells have PARP1

associated with replicating DNA Figure 3.5A and

38

. As such, it is possible that there is

cross-talk between the mtp53 R273H CTD and PARP1 such that together they influence
signal transduction for chromatin remodeling and replication associated activities.
We propose that the CTD of mtp53 promotes an interaction with PARP1 and this
enables replicating DNA to respond well to stressful conditions, thus assisting in the
coupling of leading and lagging strand DNA synthesis (see Figure 3.6). We see PARP1
binding to replicating DNA in the presence, or absence, of the mtp53 R273H CTD (Figure
3.5A). We propose that PARP1 associates with the lagging strand in MDA-MB-468 cells
and self PARylates (as has been shown in other models)

86

, which then promotes the

interaction of PARP1 with the CTD of mtp53. The mtp53-PARP1 axis may then coordinate
a bridge between mtp53 and other mtp53 binding partners like MCM2-7 and
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Topoisomerase 1 105. Nuclear PARPs are critical for maintaining genome integrity during
DNA replication, but exactly what they do in cancer cells undergoing increased genomic
instability requires further study

103

. We see that PARylated PARP1 in MDA-MB-468

breast cancer cells interacts with the CTD of mtp53 R273H, and this may allow for the
coordination of replication proteins needed to respond to replication stress (Figure 3.6).
Presently, it is not clear if the mtp53 R273H can function in replication as a
monomer. We see that in the small CTD deletion, mtp53 R273HΔ381-388, expressing
cells there is an abundance of G2/M cells after aphidicolin synchronization (Figure 3.5B
and C). It is possible that the mtp53 in these cells remains interacting with some
replication components while no longer interacting with others and this may cause more
torsional stress that can’t be resolved well in G2/M. If the role of mtp53 R273H is to help
resolve DNA replication stress by facilitating PARP1 crosstalk with other replication
proteins, then perhaps the mtp53 R273HΔ381-388 form maintains an activity that slows
replication (or resolution of replication stress intermediates) but cannot adequately finish
the job.

3.5.3 Future studies needed to determine if PARP1 activity is regulated by mtp53
and how mtp53 post-translational modification regulates PARP1 interactions.
The C-terminus of mtp53 R273H may regulate both the PARylation of mtp53, and
the interaction with PARP1, in such a way that PARP1 enzymatic activity and substrate
selection are altered. We propose that in cells missing the entire CTD, mtp53
R273HΔ347-393, the leading strand is uncoupled from the lagging strand and allows for
increased processivity as well as less replication fork asymmetry (see Figure 3.6). In cells
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with mtp53 R273HΔ381-388, the altered mtp53 may have interactions with some
PARylated PARP1, and some unPARylated PARP1, similar to what we see for the in vitro
expressed R273HΔ24 (Figure 3.3). While we do not have direct evidence for an altered
interaction mtp53 R273HΔ381-388, it remains a possibility that this mtp53 isoform has
distinct functions that will need to be identified. An alternative possibility is that PARP1
substrates are altered by different forms of the mtp53 which could result in altered cell
cycle regulation.
Our data shows that mtp53 R273H retains the ability to interact with PARP1 and
PAR through the CTD. Since it has been reported that PARP1 is a sensor of unligated
Okazaki fragments, and loss of the mtp53 R273H CTD results in a replication-based cell
cycle defect, we investigated replication fork speed through use of the DNA fiber assay.
Our data revealed that the portions of the mutant p53 R273H CTD influence the speed of
DNA replication and progression through G2/M of the cell cycle. Paradoxically, while
deletion of mutant p53 R273H amino acids 381-388 resulted in slowed DNA replication
and delayed G2/M progression, deletion of amino acids 347-393 increased replication
speed. When considering mtp53 R273HΔ347-393 has the least interaction with PARP1,
these findings are consistent with previous studies that observed replication fork speed
is increased under conditions of PARP1 inhibition or depletion

99

. Furthermore, the idea

that R273HΔ347-393 lacks some PARP1-mediated damage sensing is supported by the
absence of a statistically significant change in replication fork asymmetry – a measure of
replication fork stalling and damage resolution – between untreated and HU-treated
conditions (Figure 3.4). The model shown in Figure 3.6 depicts our interpretation of how
the CTD is participating in mtp53 R273H gain-of-function by interacting with chromatin-
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bound PARP1 and supporting efficient resolution of unligated Okazaki fragments while
slowing down leading strand synthesis to couple the two strands together.

3.5.4 Targeting PARP1 inhibition may be a valuable strategy for breast cancers that
express mutant p53 and PARP1 biomarkers.
PARP1 inhibitors with varying activities are prescribed for people with breast
cancers that have BRCA1 mutations, but not for cancers that have p53 mutations

91

.

Further understanding the relationship that mutant p53 plays in the response of cancers
to single, or combination, treatments with the new array of PARP1 inhibitors will extend
the demographics of precision medicine patients. The interplay between p53 and PARP1
is dynamic and creates a central hub that presents paradoxical relationships

34,106,107

. It

has been shown that p53 mutations can increase sensitivity to PARP1 inhibitors, and also
that loss of p53 function can block PARP-mediated NAD depletion blocking PARPmediated tumor necrosis, thus resulting in some contradictory findings

106,108

.

Immunohistochemistry can be used to detect high expression of mtp53 and PARP
proteins, both often found in breast cancers

38

. We have seen that high expression of

mtp53 R273H sensitizes breast cancer cells to killing by the combination treatment of the
PARP1 inhibitor talazoparib in combination with the chemotherapeutic agent
temozolomide 35,38. If biopsy samples could be rapidly screened for PARP1 and mtp53 as
biomarkers as one means to determine cancers that could be effectively treated with
PARP1 inhibitors, it would increase the demographic of breast cancer patients who could
benefit from personalized PARP inhibitor medicine. In the future, we will examine the role
of different missense mtp53, post-translationally modified mtp53, and complete loss of
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expression of p53, as biomarkers for consideration to use PARP1 inhibitor combination
treatments. Determining more biomarkers that address how personalized PARP inhibitorbased breast cancer therapies benefit cancer cell killing can increase the precision of
targeting this treatment to benefit more patients.
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3.7 Figure Legends:

Figure 3.1: CRISPR/Cas9-altered MDA-MB-468 and transfection constructs express
mutant p53 R273H. (A) Schematic of mutant p53 R273H protein alterations as a result
of CRISPR/Cas9 alteration or site-directed mutagenesis. (B) Western blot from whole cell
lysates comparing expression levels in MDA-MB-468, R273HΔ381-388, R273HΔ347393, and R273Hfs387 cells. (C) Western blot from whole cell lysates of HCT116 p53-/cells transfected with plasmids encoding p53 with C-terminal point mutations
(R273H6KQ, R273H6KR), or deletion (R273HΔ24). Transfection with eGFP-expressing
plasmid is used as a negative control for p53 expression.
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Figure 3.2: Loss of the CTD of R273H mtp53
decreases

mtp53-PARP1

and

mtp53-PAR

interactions. (A) Analysis of p53/PARP1 complexes by
in situ proximity ligation assay (PLA) in MDA-MB-468,
R273HΔ381-388

and

R273HΔ347-393

cells.

Fluorescent foci per cell were counted by Cellprofiler
software and depicted by a scatter plot using GraphPad
Prism 9. The data represent a scatter plot with n=3. An
ordinary one-way ANOVA was used to determine the
statistical significance of the data. The following format
was used to assign significance based on P-value: ****
represents a p-value ≤ 0.0001 and ns represent nonsignificant. Representative confocal microscope images
of p53/PARP1 foci/complexes (red) by in situ proximity
ligation assay (PLA) in MDA-MB-468, R273HΔ381-388
and R273HΔ347-393 cells. DNA was counterstained
with DAPI (blue). The z-stack maximum intensity
projection images are shown. Three independent
experiments were performed. (Scale bar = 10µm). (B)
Analysis of p53/PAR complexes by in situ proximity
ligation assay (PLA) in MDA-MB-468, R273HΔ381-388
and R273HΔ347-393 cells. Fluorescent foci per cell
were counted by Cellprofiler software and depicted by a
scatter plot using GraphPad Prism 9. The data
represent a scatter plot with n=3. An ordinary one-way
ANOVA

was

used

to

determine

the

statistical

significance of the data. The following format was used
to assign significance based on P-value: **** represents a p-value ≤ 0.0001 and ns
represent non-significant. Representative confocal microscope images of p53/PAR
foci/complexes (red) by in situ proximity ligation assay (PLA) in MDA-MB-468,
R273HΔ381-388 and R273HΔ347-393 cells. DNA was counterstained with DAPI (blue).
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The z-stack maximum intensity projection images are shown. Three independent
experiments were performed. (Scale bar = 10µm). (C) Pellets from MDA-MB-468,
R273HΔ381-388 and R273HΔ347-393 cells were lysed in RIPA buffer and lysate used
for co-immunoprecipitation assay. Samples were run on an SDS-PAGE gel and western
blot analysis performed with p53 and PARP1 antibodies. Lanes 1,4 and 7 represent the
input lanes, lanes 2,5 and 8 represent the negative control IgG lanes and lanes 3, 6 and
9 represent the p53: IP lanes. Image is a representation of 3 independent biological
replicates.
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Figure 3.3: Exogenous
CTD mutations in R273H
mtp53
not

plasmids
decrease

chromatin

does
mtp53

association

and PARP1 interaction
with PARP1. (A) HCT116
p53-/-

cells

transfected

with plasmids expressing
either

wtp53,

R273H

or

eGFP,

R273H-6KQ,

R273H-6KR or R273HΔ24
were harvested 24 hr posttransfection.

Binding

of

mtp53, PARP1, Lamin and
Actin to chromatin isolated
from partially purified lysed
nuclei

(chromatin

fractionation assay) was
assessed by western blot
analysis. 25 μg of chromatin protein was loaded on 10% SDS-PAGE gel. Image is a
representation of 3 independent biological replicates. (B) HCT116 p53-/- cells transfected
with plasmids expressing either wtp53, eGFP, R273H or R273H-6KQ, R273H-6KR or
R273HΔ24 were harvested 24 hr post-transfection. Pellets were lysed in CHAPS buffer
and lysate used for co-immunoprecipitation assay. Samples were run on an SDS-PAGE
gel and western blot analysis performed with p53, PARP1 and PAR antibodies. Lanes
1,4,7,10,13, and 16 represent the input lanes, lanes 2,5,8,11,14, and 17 represent the
negative control IgG lanes and lanes 3, 6,9,12, and 15 represent the p53: IP lanes.
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Figure 3.4: The mutant p53
R273H

C-terminal

alters

DNA

domain
replication

dynamics under hydroxyurea
treatment.
(A-D) DNA fiber assay comparing
fork

speed

in

R273HΔ381-388,

MDA-MB-468,
R273HΔ347-

393, and R273Hfs387 cells. Fork
speed was determined through
measuring the CldU length of
double

labeled

DNA

fibers.

Asymmetry ratio was determined
through measuring both arms of
newly fired origins and dividing
the length of the long arm over the
short arm of the same origin.
Three

independent

replicates

were

biological
performed.

Pairwise comparisons were made
using ANOVA. *p<0.05; **p<0.01;
****p < 0.0001; ns, not significant
p>0.0
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Figure 3.5: Mutant p53
R273H

localizes

replicating

to

DNA

changes

cell

and
cycle

dynamics
(A) Isolation of proteins on
nascent

DNA

(iPOND)

experiment comparing MDAMB-468,

R273HΔ381-388,

and R273HΔ347-393 cells.
PCNA is used as a positive
control

for

nascent

pulldown

DNA.

(B)

of

Flow

cytometry comparing MDAMB-468,

R273HΔ381-388,

and R273HΔ347-393 cells.
Cells

were

aphidicolin

treated
for

24hr

with
and

released into fresh media. Measurements were taken from 0-18hr as indicated. Three
independent biological replicates were performed but data is shown from one
independent biological replicate. (C) Summary analysis of flow cytometry data over time.
Three independent biological replicates were performed. Statistical comparisons were
made using a one-tailed student’s t-test. *p<0.05
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Figure 3.6: Model for mutant
p53 C-terminal domain crosstalk with PARP1 replicating
DNA
Our data indicates that the
mtp53 R273H CTD interacts with
replicating DNA, PARP1, and
poly-ADP-Ribose independent of tetramerization. We predict in our model that this
interaction occurs on the lagging strand of DNA replication forks and assists in the efficient
resolution of DNA replication stress in cancer cells. PCNA-Proliferating Cell Nuclear
Antigen, MCM2-7 Mini chromosome Maintenance Complex 2-7, SSB- Single stranded
Binding protein. This model was created using Biorender.
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Supplementary Figures

Figure S3.1: Exogenous CTD mutations in R273H mtp53 plasmids does not
decrease the interaction between mtp53 with PARP1.

HCT116 p53-/- cells

transfected with plasmids expressing either wtp53, eGFP, R273H or R273H-6KQ,
R273H-6KR or R273HΔ24 were harvested 24 hr post-transfection. Pellets were lysed in
CHAPS buffer and lysate used for co-immunoprecipitation assay. Samples were run on
an SDS-PAGE gel and western blot analysis performed with p53, PARP1 and PAR
antibodies. Lanes 1,4,7,10,13, and 16 represent the input lanes, lanes 2,5,8,11,14, and
17 represent the negative control IgG lanes and lanes 3, 6,9,12, and 15 represent the
p53: IP lanes.
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Figure S3.2: Origin firing is unaltered following HU-induced DNA replication stress
in mtp53 R273H dual mutants
Origin firing was measured using double labeled fibers from the DNA fiber dataset
presented in figure 4. Data was from 3 independent biological replicates. There was no
statistically significant difference between pairwise comparisons made using a normal
one-way ANOVA examining all conditions.
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CHAPTER 4

Conclusion and Future Directions
4.1 Conclusion

The dissertation research study presented herein focused on understanding the role
of the oligomerization and C-terminal domains of mtp53 in its oncogenic GOF activities.
Ever since David Lane and Arnold Levine discovered the p53 protein, extensive research
has explored the importance of each domain to the overall functionality of wtp53 as a
tumor suppressor. What has been abundantly clear throughout the years is the
importance of the OD and CTD in enabling the DNA binding ability of wtp53. This DNA
binding is critical and results in the transcriptional activation of wtp53 target genes. In
wtp53 expressing cells, mutations in either the OD or CTD significantly abrogates the
ability of wtp53 to transactivate the necessary target genes. Thus, showing that the OD
and CTD are critical for wtp53 to perform normal tumor suppressor functions. The
oncogenic GOF mtp53 ability is attributed to the presence of specific missense mutations
within the DBD of p53. Even though the OD and CTD have been shown to be of critical
importance to the activities of wtp53, little is known about the importance of these domains
to the GOF functionality of mtp53. In this dissertation, we aimed to bridge this gap in our
knowledge by elucidating how the OD and CTD regulate mtp53 GOF activities. To this
end, we hypothesized that an intact CTD and a tetrameric mtp53 conformation regulated
the oncogenic GOF activities of mtp53.
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This study is the first to report the generation of a dual DBD and OD/CTD mtp53 which
was used to interrogate the importance of the OD and CTD to mtp53 GOF activities. We
introduced mutations by site directed mutagenesis within the OD or CTD of mtp53
expressing plasmids for exogenous expression of dual mutants. We used CRISPR/Cas9
mediated mutagenesis to introduce mutations into the endogenous single locus of MDAMB-468 cells (a triple negative breast cancer cell line) expressing the R273H hotspot
mtp53. We observed destabilization of tetramerization of mtp53 by introducing LFS OD
point mutations within the OD of R273H expressing plasmids. Also, the ability of R273H
mtp53 to form tetramers in cells was lost in clones with a deletion of a portions of the OD
plus deletion of the entire CTD 93,109.
Mutations in p53 are found in more than 50% of all cancers. GOF mtp53 is at the heart
of a myriad of biological activities which enables it to enhance the tumorigenicity of cells
expressing the protein, but the mechanisms are still be elucidated. Contrary to previous
report42, our data did not support a significant upregulation of mtp53 target genes CDC7
and RRM2 by plasmids exogenously expressing R273H mtp53. However, even in the
absence of upregulated gene expression we observed that exogenous expression of the
dual mtp53 R273H-L344P significantly downregulated the expression of CDC7 and
RRM2. Our inability to observe upregulation of CDC7 and RRM2 by expression of mtp53
R273H might be due to an absence of aneuploidy (in our cell line) which has been
correlated with some of the transcription dependent activation properties54. Also, the fact
that we didn’t have a transfection efficiency of not more than 20-30% was a major
challenge for the transcriptional analysis of this research study.
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We previously established that transcription independent GOF associates with
chromatin associated mtp53, PARP1 and MCM2 and call this the mtp53-PARP1-MCM
axis35. The mtp53 proteins associates with replicating DNA and PARP1. Herein, we
assessed the importance of the OD or CTD to this axis as well as the importance of the
CTD to the association of mtp53 on replicating DNA. We showed that mtp53 does not
need to assume a tetrameric configuration in order to associate with chromatin, PARP1
or MCM2. On the other hand, we observed that deletion of the entire CTD and portions
of the OD decreased the association of mtp53 with chromatin, PARP1 and MCM2.
However, we did not see that these changes reduced PARP or PCNA on replicating DNA.
This observation suggested that the chromatin associated function of GOF mtp53 is, to a
large extent, regulated by the CTD more than it is by the OD. This observation was made
in part due to our data showing that even though both R273H-L344P and R273HΔ347393 were predominantly monomeric, it was only the large deletion (R273HΔ347-393) that
resulted in a significant reduction in chromatin association and interaction with PARP1
and MCM293. Also, we observed that deletions within the CTD (R273HΔ381-388) as well
as deletion of the entire CTD and portion of the OD (R273HΔ347-393) both reduced the
levels of mtp53 on the chromatin. The CTD of p53 is rich is lysine which easily interact
with the phosphate backbone of DNA. A possible explanation to this observation is that
the deletion of three lysines in R273HΔ381-388 as well as all six lysines in R273HΔ347393 resulted in a decreased association with replicating DNA.
Taken together, questions asked in this dissertation uncovered the importance of the
OD and CTD to mtp53 GOF oncogenic activities. Based on our data, we suggest that the
CTD is critical for the oncogenic GOF mtp53 activity. The working model for this research
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study as depicted in Figure 4.1 suggests that irrespective of the oligomerization state of
mtp53, it can associate with chromatin and interact with PARP1 and MCM2. This
interaction however is reduced when the entire CTD is deleted.
Our data indicates that the mtp53 R273H CTD interacts with replicating DNA, PARP1,
and poly-ADP-Ribose independent of tetramerization. Thus, irrespective of the
oligomerization state, mtp53 firmly tethers to chromatin and replication associated factors.
However, this interaction is lost or reduced by losing the CTD. Further studies to
understand how the OD and CTD regulate tumor formation in vivo as well as assessing
the consequence of endogenous OD mutation is in progress and discussed in the next
section.

Figure 4.1 Model highlighting the importance of the CTD in orchestrating the
association of mtp53 to replicating DNA and replication associated factors.
The DNA replication machinery depicted with the CTD of mtp53 regulating association of
mtp53 with key replication associated proteins.
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4.2 Future Directions and Preliminary Data
Having successfully generated and characterized OD and CTD specific GOF mtp53
clones, we reported differences in the proliferation rate of these clones compared to the
parental R273H expressing cells35. This observation has laid down the foundation for our
current in vivo work. We explored how orthotopic implantation of NOD scid gamma (NSG)
mice with MDA-MB-468 cells expressing the R273H GOF mtp53 compared to the
R273HΔ347-393 and R273Hfs387 clones in terms of tumor formation and number of
circulating tumor cells (CTC). Based on our published in vitro results35, we expected to
see that, compared to the NSG mice implanted with R273H expressing MDA-MB-468
cells, those implanted with R273HΔ347-393 cells would result in decreased tumor
formation and reduced number of CTCs. Also, the frameshift mutant R273Hfs387 which
express little to no mtp53 was expected to form smaller tumors and have a reduced CTC
count.
We observed that all mice implanted with cells expressing full length R273H mtp53
formed tumors after barely two weeks post-implantation (Figure 4.2A). The mice
implanted with cells expressing R273HΔ347-393 or R273Hfs387 mtp53 as predicted did
not form tumors two weeks post-implantation. The first tumor was observed for mice
implanted with R273Hfs387 cells at about three weeks post-implantation while those
implanted with R273HΔ347-393 formed tiny tumors at about three and a half weeks postimplantation. Over the course of the experiment, it was observed that the mice implanted
with R273Hfs387 cells looked sick (there was no clear explanation for this available at the
time of writing this thesis) and the endpoint was set at seven weeks post implantation. At
necropsy, we measured the sizes of each harvested tumor and compared the tumor
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volumes. We observed a significant reduction in tumor volume when the tumors from
mice implanted with R273HΔ347-393 or R273Hfs387 were compared to tumors from
those implanted with R273H (Figure 4.2B).
Figure 4.2: The OD and CTD
regulate tumor growth and
CTC

count.

MDA-MB-468

cells which express R273H,
and clones (R273HΔ347-393
or R273Hfs387) generated via
CRISPR/Cas9 gene editing
were orthotopically implanted
in NSG mice. Each mouse
was implanted with 5x10^6
cells in 100 µl of a 1:1
DMEM:Matrigel. Tumor size
was measured two weeks
post-implantation

with

a

caliper. The length (L) and
width (W) of the tumor were
measured and the formula
½*(LxW2)

was

used

to

calculate the tumor volume.
(A) A representation of tumors measured at various timepoints post implantation. (B) A
representation of tumor volumes at necropsy. (C) Circulating Tumor Cells (CTCs) were
extracted from mouse blood. The number of human (hu) EGFR expressed was measured
via flow cytometry and graphically depicted.
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Mtp53 expressing cancer cell lines (MDA-MB-231 and MDA-MB-486) have been
documented to have metastatic potential in mouse xenograft models110,111. One way of
assessing metastatic potential of primary tumor is to determine the number of circulating
tumor cells (CTCs) found in the blood. The higher the number of CTCs in the blood, the
higher the level of intravasation which is an initial characteristic of metastatic tumors. We
sought out to determine the number of CTCs by using the cell surface marker human
Epidermal Growth Factor Receptor (hu-EGFR). Hu-EGFR is highly expressed in MDAMB-468 cells. We first assessed the protein expression levels of hu-EGFR in mtp53
R273H, R273HΔ347-393 or R273Hfs387 expressing cells via western blot analysis. We
observed that in each cell, we detect a significant expression of hu-EGFR. For the CTC
count, CTCs were extracted from blood collected from each mouse at endpoint. We first
confirmed the expression levels of the hu-EGFR via western blot analysis of lysate from
R273H, R273HΔ347-393, or R273Hfs387 cells. Using flow cytometry, we measured the
expression levels of hu-EGFR as a measure of the number of CTCs extracted from each
blood sample from the mice. We observed that CTCs generated from the blood of mice
implanted with R273H expressing MDA-MB-468 cells had the highest levels of EGFR as
compared to those implanted with R273HΔ347-393 or R273Hfs387 cells (Figure 4.2C).
These preliminary data suggest that the ability of R273H GOF mtp53 expressing cells to
induce tumor formation in vivo and affect the levels of the CTCs was controlled in part by
the levels of mtp53 (as evident by the decrease in tumor volume and CTCs in the
R273Hfs387 clone) as well as the CTD (as evident by the reduced tumor volume and
CTCs in the R273HΔ347-393). To adequately confirm whether the reduced number of
CTCs observed in mice implanted with R273HΔ347-393 or R273Hfs387 expressing
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mtp53 cells were due to either low levels of mtp53 or the absence of the CTD and portion
of the OD, we recommend the following.
Firstly, we observed that when a fixed number of cells were implanted in each mouse
(5x10^6 cells), it led to different tumor size. To eliminate the possibility of the differences
observed in tumor size being responsible for the decreased in CTC counts observed in
mice implanted with R273HΔ347-393 or R273Hfs387 expressing mtp53 cells, we
recommend orthotopically implanting mice with different number of R273H (1x10^6 cells),
R273HΔ347-393 (5x10^6 cells) or R273Hfs387 (4x10^6 cells) in each mouse group (5
mice per group). After implantation, the tumor size should be measured when the mice
implanted with R273H cells start forming tumors. The tumors should be measured
continuously until they reach specific dimension (example 9x9). At this dimension, the
mice should be sacrificed, and blood collected into heparin coated tubes for CTC
extraction. For the mice implanted with R273HΔ347-393 or R273Hfs387, the tumor size
should be measured, and the mice sacrificed, and blood collected into heparin coated
tubes when they reach the stipulated dimension of 9x9. If the number of CTC depends
on the levels of mtp53 or the absence of the CTD and part of the OD, we expect to see a
similar result to that in figure 4.2C. On the other hand, if the low number of CTCs observed
in figure 4.2C was due to smaller tumor size, we expect to see mice implanted with
R273H, R273HΔ347-393 or R273Hfs387 expressing mtp53 have relatively similar
number of CTCs. With the large tumors from this experimental plan, we recommend
exploring the difference in expression levels of Epithelial-Mesenchymal Transition (EMT)
specific genes. Differential expression levels of E-Cadherin, N-Cadherin, Vimentin, Slug1,
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and Snail1 will give an indication of the metastatic potential associated with the mice
implanted with R273H, R273HΔ347-393 or R273Hfs387 expressing mtp53.
An initial goal at the start of this dissertation study was to use CRISPR/Cas9 gene
editing to generate clones that express point mutations within the OD of mtp53. After
years of not successfully obtaining the mutants of interest, we recently made headway.
Through the effort of the team particularly Mr. Don-Gerard Conde, we have a mixed pool
which has a population with about 50% of the desired L344P mutation. We are in the
process of selecting for the R273H-L344P clone using a cloning cylinder method. We will
confirm the clones for loss of mtp53 oligomerization via glutaraldehyde crosslinking assay
and western blot analysis (as we first published with our initial work with R273H-L344P
expressing plasmid)93 .
To further confirm the role of the OD in mtp53 oncogenic GOF activities, we
recommend repeating all the experiments that have been done with the R273H-L344P
expressing plasmids. This is of outmost importance in part due to the endogenous
R273H-L344P pool having an entire population of cells expressing this mutation, an
option that we weren’t guaranteed from a transient transfection setup. This will help
elucidate the mechanistic role of how the OD regulates oncogenic mtp53 GOF activities.
We previously used qPCR to compare the mRNA expression of CDC7 and RRM2
between mtp53 R273H expressing MDA-MB-468 and dual-mutant R273HΔ347-393 cells.
We observed a significant decrease in the mRNA expression levels of CDC7 and RRM2
when mtp53 R273HΔ347-393 expressing cells were compared to mtp53 R273H109. Since
the mtp53 R273HΔ347-393 and R273H-L344P clones are both predominantly
monomeric, we suggest querying the variations in mRNA expression levels of CDC7 and
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RRM2 between mtp53 R273H and R273H-L344P cells. Also, chromatin fractionation,
PLA and iPOND can be used to interrogate mtp53 chromatin levels, interaction with
PARP1 or MCM2 and association with replicating DNA respectively.
With the success made with the first endogenous clone (R273H-L344P), another
major future experiment will be designing new guide RNA (gRNA) and homology directed
repair (HDR) donor template to introduce other OD and CTD mutations highlighted in this
dissertation.
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